

EFI 2023

36TH EUROPEAN IMMUNOGENETICS AND HISTOCOMPATIBILITY CONFERENCE

April 26–29, 2023, Nantes, France

Big Data in Immunogenetics at the Crossroads of Care, Tools and Research

FINAL PROGRAM




CONTENT



WELCOME ADDRESS

Dear scientists, dear EFI members,

On behalf of the Local Organizing Committee, we are happy to welcome you to Nantes on April 26–29, 2023, for the 36th European Immunogenetics and Histocompatibility Conference. Nearly 15 years after the last EFI meeting in the south-west of France, in Toulouse, in 2008.

A generation of immunogeneticists has taken over from their mentors, but our field remains more than ever at the crossroads of clinical applications in transplantation, technological tools that have evolved with the ability to crunch large amounts of data, and basic science that is changing our understanding of the immune system and its genetic determinants. Our field is a perfect example of the "Pasteur quadrant", the type of science named after one of France's most inspirational scientists, Louis Pasteur: At heart, immunogenetics is a sum of basic research inspired by use.

The theme for this year's conference is "Big Data in Immunogenetics at the Crossroads of Care, Tools, and Research" shedding the light on new challenges of immunogenetics. For example, the development of new tools to inform the decision-making process in health will come from the integration of population-based immunogenomics data with modern machine learning applications.

The conference will stimulate scientists, clinicians, students, and industry from around the world to present innovative and significant research and clinical innovations in the field of immunogenetics and histocompatibility.

We would like to express our gratitude to EFI for giving us the honor to host this meeting, the EFI Executive Committee, the EFI Scientific Committee, the EFI Education Committee and Members of the Local Organizing Committee. They have all provided us with precious help and support in preparation of the Scientific Program, teaching sessions.

Without the generous support provided by our sponsors and GUARANT Int. the newly appointed professional conference organizer of EFI, this conference would not have been possible at this scale.

Together with all the LOC members and our CR2TI research group, we welcome you all to Nantes in April 2023, to participate in what we hope will be an inspiring meeting both scientifically and socially!

Prof. Pierre-Antoine Gourraud
Chair, On behalf of the 36th EFI Conference Local Organizing Committee

PARTNERS AND EXHIBITORS

WE WOULD LIKE TO THANK THE FOLLOWING PARTNERS FOR THEIR SUPPORT

Platinum Partners

CareDx®
Your Partner in Transplant Care™

GENDX

IMMUCOR®

ONE LAMBDA
A Thermo Fisher Scientific Brand

Gold Partner

omixon

Silver Partner

Dvysr®

Bronze Partners

DKMS
Life Science Lab

HISTOGENETICS

BAG DIAGNOSTICS

HANSA BIOPHARMA

STEMCELL™ TECHNOLOGIES

Special thanks to:

CareDx® Your Partner in Transplant Care™

Navigation System Partner
& Lanyards Partner

HISTOGENETICS

The Wine and Cheese
Poster Session Partner

GENDX

Tulip Run Partner

Nantes St-Nazaire Bureau des Congrès

City Support

ONE LAMBDA
A Thermo Fisher Scientific Brand

Welcome Cocktail Partner

Exhibitors

ATC TRUSTED PARTNER IN GENOMICS

DiagnoSeq Life of Gene

bionobis

inno-train 25 DIAGNOSTIK

JETA MOLECULAR

médiane diagnostics

PIRCHE® match better.

protrans medizinische diagnostische produkte gmbh

TBG

UK NEQAS Histocompatibility & Immunogenetics



CareDx®

AlloSeq HCT

Revolutionizing Chimerism Monitoring

STREAMLINED WORKFLOW | AUTOMATED ANALYSIS | COMPREHENSIVE SOFTWARE QUALITY METRICS

Jen R.,
Stem Cell and Double Lung Transplant Recipient

- 1-step single reaction multiplexed PCR
- 1 assay for genotyping and monitoring
- Targets 202 bi-allelic SNPs across 22 autosomes
- Test up to 48 samples/run
- 0.22% Limit of Detection
- gDNA Sample to Report in Less than 24 hours

AMPLIFICATION & SEQUENCING

EXTRACTED DNA

1. **PCR**
   1hr 45 mins TAT | 45 mins HOT
2. **POOL + CLEAN**
   1hr TAT | 35 mins HOT
3. **QUANT + LOAD**
   30 mins TAT | 15 mins HOT
4. **SEQUENCING**
   17 hrs
   Validated for Illumina MiSeq
5. **TRANSFER**
   Import FASTQ files
   ANALYZE
   Generate QC Values and % gDNA
   REPORT
   Export results to Excel and LIMS-compatible file

*References for early rejection • Rashef et al BBMT 2014;20:1758–66 • Tang et al BBMT 2014;20:1139:1144

*HOT: Hand-on Time (based on 48 samples) *TAT: Turn around time

For more information visit www.caredx.com/alloseq-hct or contact your CareDx representative.

MAR118 Revision 1 Effective 2022-08

NGSTRACK® & TRKENGINE®

YOUR SOLUTION FOR NGS CHIMERISM MONITORING

From DNA to sequencing in < 2.5h
Quick & easy data analysis with TRKengine

- Higher sensitivity than STR
- 34 indel markers
- Single pre-sample sufficient
- Reliable at all chimerism percentages

Order now or request a demo via sales@gendx.com

experts in transplant diagnostics

GENDX

Yalelaan 48 | 3584 CM Utrecht | Utrecht Science Park
The Netherlands | +31 (0)30 252 3799 | www.GenDx.com

Seeing Beyond Limits

Visit Immucor Booth #3 at EFI 2023

26th - 29th April 2023, Nantes, France

Schedule a live in booth demo of our **MIA FORA® NGS *EXPRESS*** software or **NEW MATCH IT!® Antibody v1.5**

CLICK HERE
to find out more information on all of these exciting events!

HAVE YOUR SAY!
Participate in an interview to shape our Next Gen software

Wednesday 26th April

Join us for a **MATCH IT!® Antibody** software workshop!

Thursday 27th April

Immucor's Sponsored Symposium

Exploring New Frontiers in Transplantation Testing

Room 300 Lower Foyer
1:30pm - 2:30pm

Head over to immucor.com/efi2023 and follow us on social media for the latest news.

IMMUCOR



Dr. Paul Terasaki
Transplant Pioneer

ThermoFisher SCIENTIFIC

20

LABScreen Single Antigen Bead

A Revolution in Transplant Diagnostics

20th Anniversary of the One Lambda LABScreen Single Antigen Bead

Twenty years ago, the One Lambda™ LABScreen™ Single Antigen Bead assay was introduced and quickly became the standard for antibody screening and monitoring. Since then, our collaboration with the Transplant Community has resulted in the introduction of new practices that've helped improve patient transplantation.

The Single Antigen Bead Technology has enabled groundbreaking work in transplantation and has been critical to the understanding of *de novo* DSA post-transplant. This year is not just about celebrating a 20th Anniversary, it's about celebrating our global collaborations and the impact we've all had in improving the quality of life for transplant patients worldwide.

Visit us at EFI at booth #4

ONE LAMBDA
A Thermo Fisher Scientific Brand

EFI 2023

MEET OMIXON AT EFI 2023

SEE YOU AT BOOTH #5

April 26-29, 2023

Cité des congrès de Nantes
Nantes, France

OMIXON EVENTS AT EFI 2023

Experience the Future of HLA Typing - Omixon User Group Meeting

PRIVATE EVENT

WHEN?
Wednesday 26th April

Please subscribe at
sales@omixon.com

New horizons in HLA Typing - Omixon's Symposium

WHEN?
Friday 28th April,
14:30-15:30

WHERE?
Lower Foyer,
Room 150

Wim Adriaensen, PhD
Clinical Immunology
Institute of Tropical Medicine

Dr. rer. nat. Claudia Lehmann
Transplantation Immunology
University Hospital Leipzig

Prof., Dr. rer. nat., Dipl. Biol. Ilias Doxiadis
Transplantation Immunology
University Hospital Leipzig

CONFERENCE INFORMATION

CONFERENCE VENUE

La Cité des Congrès de Nantes
Nantes Events Center
5 rue de Valmy
BP 24102
44041 Nantes cedex 1
www.lacite-nantes.com/



EXHIBITION PLAN



List of Exhibitors

1 CareDx
2 GenDx
3 Immucor Inc.
4 One Lambda a Thermo Fisher Brand
5 Omixon Ltd.
6 Devyser
7 Hansa Biopharma
8 EFI 2024
9 ATC Genomics
10 EFI
11 DKMS Life Science Lab gGmbH
12 STEMCELL Technologies
14 BAG Diagnostics GmbH
15 Histogenetics
16 inno-train Diagnostik GmbH
18 SAS médiane diagnostics
19 JETA Molecular BV
20 Bionobis
21 TBG Biotechnology Corp.
23 UK NEQAS for H&I
24 PROTRANS
25 PIRCHE

You are more than welcome to visit the EFI booth in stand number 10 at April 27 from 8:30–17:00 and April 28 from 8:30–16:30.

FREE WI-FI

SSID: 0-la Cite Guests
Password: cite2023

EFI 2023 MOBILE APPLICATION

With the mobile application, you will have access to the detailed program and all the important information related to the conferece.

Download the mobile app in the App Store / Google Play.

Available on the App Store

GET IT ON Google play

EFI 2023

EFI SOCIAL MEDIA

Follow EFI on Social Media
Facebook https://www.facebook.com/EFI2023
Twitter https://twitter.com/ConferenceEfi?s=20
LinkedIn linkedin.com/company/efi-conference-2023/

As for EFI conference 2023 use #EFI2023.

REGITRATION

SELF-CHECK-IN

On-site registration and issue of badges will take place at self-check-in stations. You will receive a QR code before the conference via email. You can print the QR code or use your mobile devise to obtain your badge.

On-site Registration Fee

Member	720 EUR
Non-member	820 EUR
Technician	490 EUR
Student	490 EUR
Retired	490 EUR
One-day fee (April 27/28)	510 EUR
One-day fee (April 29)	410 EUR
Distributors	250 EUR
Accompanying Person	150 EUR

Registration fee include 20 % VAT.

The Registration Fee Includes:
- Access to the conference and all its sessions (not included for Accompanying Persons)
- Welcome cocktail
- Opening ceremony
- Coffee and lunch breaks
- Wine and cheese poster session

The distributor fee allows for access to the exhibition only. Access to the sessions need a full conference ticket.

The One-day Registration Fee Includes:
- Access to the conference and all sessions taking place on the selected day
- Coffee and lunch breaks

The Accompanying person´s Registration Fee includes:
- Access to the building and exhibition
- Welcome cocktail
- Wine and cheese poster session
- Accompanying persons do not have access to scientific sessions

REGISTRATION DESK

Opening Hours:

Wednesday, April 26, 2023	08:00–18:00
Thursday, April 27, 2023	07:00–18:30
Friday, April 28, 2023	08:00–18:00
Saturday, April 29, 2023	08:00–14:00

NAME BADGE

All delegates will receive a name badge upon registration. Everyone is kindly requested to wear his/her badge when attending the conference.

DELEGATE

ONE-DAY FEE 27/28/29

SPEAKER

PARTNER / EXHIBITOR

ORGANIZER

ACCOMPANYING PERSON

GUEST

VOLUNTEER

CERTIFICATE OF ATTENDANCE

All delegates will receive a certificate of attendance after the conference by email.

BOOK OF ABSTRACTS

If you are an EFI member, you can view this year's Book of Abstracts after logging in on the official page of EFI.

INSTRUCTIONS FOR SPEAKERS

INSTRUCTIONS FOR ORAL PRESENTATION

Each presenter will be given a time slot of 10 minutes in total. Each oral presentation should not exceed 8 minutes. It will be followed by 2 minutes discussion.

All speakers are requested to strictly keep their allocated time slots. Session chairs will enforce the schedule.

SPEAKERS' READY ROOM

All session halls are equipped with standard PowerPoint presentation facilities. All presentations will be networked to the appropriate room "Speakers' Ready Room" (Room BC, located in the lower foyer at the venue). All speakers are asked to submit their presentations to the speakers' Ready Room at least 1 hour prior to the session you present in. Early morning presentation; Please submit your presentation the day before.

Save the file according to the following format:
<day of presentation>_<A. Session #>_<presenters name>_<title of presentation>

We kindly ask you to hand in your presentation to the technical staff in the Speakers' Ready Room on-site via an external drive. While doing so, we encourage speakers to verify their presentation. This will ensure no formatting errors.

IT support will be available in all the conference rooms during live sessions. All speakers are kindly requested to use provided PC onsite. Please be present in the session room 15 minutes before the start of your session and follow the instructions from the Chairs and/or technician. During your presentation, a remote control will be available for controlling your presentation.

At the end of the Symposium, all presentations will be deleted from the presentation system and computers on-site.

SPEAKERS READY ROOM

Opening hours:

Wednesday, April 26, 2023	15:30–20:00
Thursday, April 27, 2023	07:00–18:00
Friday, April 28, 2023	08:00–17:30
Saturday, April 29, 2023	08:00–13:00

INSTRUCTIONS FOR POSTER PRESENTERS

All posters will be displayed on poster boards (printed posters) and will be available during all sessions of the conference.

Posters must be in a portrait-oriented A0 format (width x height) (841 × 1189 mm / 33.1 × 46.8 in) which will be displayed on the boards in the Poster Hall (Mezzanine, Upper Foyer at the venue).

The presentation number assigned to your poster should not be placed on your poster. Please check the poster list carefully to make sure you hang the poster on the correct poster board.

ORGANISERS AND COMMITTEES

EFI EXECUTIVE COMMITTEE

Ann-Margaret Little (United Kingdom), *President*
Dave Roelen (The Netherlands), *Secretary*
Kay Poulton (United Kingdom), *Deputy Secretary*
Jean Villard (Switzerland), *Treasurer*
Paul Rouzaire (France), *Deputy Treasurer*
Esteban Arrieta-Bolanos (Germany), *Councillor*
Neema Mayor (United Kingdom), *Councillor*
Marie Schaffer (Sweden), *Councillor*
Antonij Slavcev (Czech Republic), *Councillor*
Luca Vago (Italy), *Councillor*
David Turner (United Kingdom), *Councillor*

EFI SCIENTIFIC COMMITTEE AND ABSTRACT REVIEWERS

Luca Vago (Italy), *Chair*
Katharina Fleischhauer (Germany)
Silvia Gregori (Italy)
Sebastiaan Heidt (The Netherlands)
James Robinson (United Kingdom)
Alicia Sanchez-Mazas (Switzerland)
Pietro Crivello (Germany)
Raphael Carapito (France)
John Trowsdale (United Kingdom)
Lotte Wieten (The Netherlands)
Pierre-Antoine Gourraud (France), *Ex-officio member*

EFI EDUCATION COMMITTEE

Deborah Sage (United Kingdom), *Chair*
Benedetta Mazzi (Italy)
Valerie Dubois (France)
Monika Lindemann (Germany)
Michael Eikmans (The Netherlands)
Marte Viken (Norway)
Katarzyna Bogunia-Kubik (Poland)
Manuel Muro (Spain)
Maria Spryropoulou-Vlachou (Greece)

LOCAL ORGANISING COMMITTEE

Pierre-Antoine Gourraud (Nantes Université, France), *Chair of the LOC*
Sonia Bourguiba-Hachemi (France)
Nicolas Vince (France)
Sophie Limou (France)
Sophie Brouard (France)
Katia Gagne (France)
Alexandre Walencik (France)
Florent Delbos (France)
Gwendaline Guidicelli (France)
Gilles Blancho (France)
Magali Giral (France)
Jean Luc Taupin (France)
Christelle Retière (France)
Valérie Dubois (France)
Patrice Chevalier (France)
Régis Josien (France)
Philippe Moreau (France)

SPEAKERS

PLENARY SESSION SPEAKERS

Florent Malard
Sorbonne Université, Hôpital Saint-Antoine, AP-HP, Paris, France

Robert Zeiser
Hematology and Oncology, University Medical Center Freiburg, Germany

Carole Guillonneau
Nantes Université, CR2TI, UMR 1064, Nantes, France

Julian Knight
Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, UK

Patrick Sulem
deCODE genetics, Reykjavik, Iceland

Corey T Watson
Department of Biochemistry and Molecular Genetics, University of Louisville School of Medicine

Seiamak Barham
INSERM U1109, Molecular ImmunoRheumatology Unit, University of Strasbourg, France

Anat Tambur
Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

Olga Timofeeva
MedStar Georgetown University Hospital, Washington D.C, USA

Soumya Raychaudhuri
(1) Brigham and Women's Hospital, (2) Harvard Medical School, and (3) Broad Institute (USA)

Marta Alarcon Riquelme
Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, Spain

Patrick Deelen
Department of Genetics, University Medical Center Groningen, Groningen, the Netherlands

Marco Salvetti
Department of Neurosciences, Mental Health and Sensory Organs (NESMOS), Neurology Residency Program, Sapienza University, Italy

Hedda Wardemann
Division of B Cell Immunology, German Cancer Research Center, Heidelberg, Germany

Darragh Duffy
Institut Pasteur, Laboratory of Dendritic Cell Immunobiology, INSERM U1223, Department of Immunology, Paris, France

EDUCATIONAL SESSION SPEAKERS

Martijn van den Hoogen
Department of Pulmonary Medicine, Division of Lung Transplantation & Erasmus MC Transplant Institute, Rotterdam, The Netherlands

Begoña Aran
Barcelona Stem Cell Bank, Regenerative Medicine Programme, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain

Paul Olivier Rouzaire
Department of Histocompatibility & Immunogenetics, Clermont Auvergne University, France

Emmanuelle Génin
INSERM UMR1078, UFR Médecine, Université de Bretagne Occidentale, France

Erick Castelli
Department of Pathology, School of Medicine, São Paulo State University (Unesp), Botucatu, State of São Paulo, Brazil

Christelle Retière
Nantes Université, EFS, INSERM, CNRS, CRCI2NA, Nantes, France

Eric Spierings
Division Laboratories, Pharmacy and Biomedical Genetics, Central Diagnostics Laboratory, Center of Translational Immunology, HLA and Tissue Typing, University Medical Center Utrecht, Netherlands

Yang Luo
The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK

Jean-Baptiste Woillard
Service de Pharmacologie, Toxicologie et Pharmacovigilance, CBRS CHU Limoges, INSERMU1248, Faculté de Médecine de Limoges, Université de Limoges, France

JOINT EFI-ESOT SESSION SPEAKERS

Gabriel Oniscu
Karolinska Institutet Stockholm, Sweden

Sophie Limou
Nantes Université, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France

Jasper Callemeyn
Nephrology and Renal Transplantation Research Group, KU Leuven, Belgium

JOINT EFI-NAT SESSION SPEAKERS

Alberto Sanchez Fueyo
The Institute of Liver Studies at King's College London, UK

Mübeccel Akdis
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Switzerland

Sophie Hillion
U1227, LBAI, University of Brest, Inserm, and CHU Brest, Brest, France

JOINT EFI-SIP SESSION SPEAKERS

Ami Bhatt
Departments of Medicine (Hematology & BMT) and Genetics, Stanford University, USA

Becca Asquith
Imperial college London, UK

Effie Petersdorf
Madeline Dabney Adams Endowed Chair in AML Research, Fred Hutchinson Cancer Center, Seattle, USA

MEET THE EXPERTS & YOUNG EFI GROUP SESSION

Dominique Charron
Steven Marsh
Katharina Fleischhauer
Ronald Bontrop

PROGRAM AT GLANCE

ASSOCIATED MEETINGS

TUESDAY, April 25, 2023	
Room 150 *(Lower Foyer)*	
09:00–17:15	Inspectors Workshop
Rooms E & F *(Lower Foyer)*	
08:30–17:30	ESHI Diploma Examination

WEDNESDAY, April 26, 2023	
Room D *(Lower Foyer)*	
08:30–16:30	Executive Committee meeting
Room E *(Lower Foyer)*	
08:30–16:30	External Proficiency Testing Committee meeting
Room F *(Lower Foyer)*	
09:00–12:00	IT & Bioinformatics Committee meeting
Room H *(Upper Foyer)*	
08:30–17:00	Accreditation Committee meeting
Room M *(Upper Foyer)*	
08:30–16:30	Standards Committee meeting
Room I *(Upper Foyer)*	
13:30–17:00	Education Committee meeting
Room K+L *(Upper Foyer)*	
12:15–13:45	Open Meeting of the Population Genetics Working Group
14:00–17:00	Scientific Committee meeting
Room G *(Upper Foyer)*	
14:30–16:30	Young EFI Working Group
Journée scientifique de la Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI)	
Auditorium 450 *(Upper Foyer)*	
13:30–16:30	SFHI Associated EFI meeting

SCIENTIFIC PROGRAM

WEDNESDAY, April 26, 2023

Great Auditorium

17:30–19:20 **OPENING CEREMONY**

Great Auditorium + Great Gallery foyers

19:30–21:00 **Welcome Cocktail**

THURSDAY, April 27, 2023

Great Auditorium

08:30–10:00 **PLENARY SESSION I**

Cell Therapies & Hematopoietic stem-cell transplantation

PARALLEL SESSIONS

Great Auditorium

10:30–12:00 **Special Joint EFI-ESOT Session**

The use of AI to Assist Decision Making in Transplantation

Room 300 *(Lower Foyer)*

10:30–12:00 **Teaching Session 1**

Innovation in Transplantation

Auditorium 450 *(Upper Foyer)*

10:30–12:00 **Abstract Session 1: MHC Evolution, Population Genetics (O9-O16)**

Room 200 *(Upper Foyer)*

10:30–12:00 **Abstract Session 2: New Technologies & New Approaches in Immunogenetics (O17-O24)**

Room 300 *(Lower Foyer)*

12:10–13:10 **Industry Symposium: CareDx**
13:20–14:20 **Industry Symposium: Immucor**

Room G *(Upper Foyer)*

12:00–14:30 **EFI Executive Committee and Coordinators meeting**

Room I *(Upper Foyer)*

13:30–14:30 **ETHIQ Diploma meeting**

Room J *(Upper Foyer)*

12:00–14:00 **SHLARC Consortium meeting**

Great Auditorium

14:30–16:00 **Special Joint EFI-NAT Session**

Control of The Immune System in Transplantation

Room 300 *(Lower Foyer)*

14:30–16:00 **Teaching Session 2**

Anthropology & Population Genetics: Immunogenetic diversity of the HLA system

Auditorium 450 *(Upper Foyer)*

14:30–16:00 **Abstract Session 3: NK Cells & KIR (O25-O32)**

Room 200 *(Upper Foyer)*

14:30–16:00 **Abstract Session 4: Immunogenetics in Organ Transplantation (O33-O40)**

Great Auditorium

16:30–18:00 **PLENARY SESSION II**

HLA Immunogenetics, Population genetics & Evolution

Mezzanine *(Upper Foyer)*

18:00–20:00 **Poster Viewing Session**

FRIDAY, April 28, 2023

Great Auditorium

08:30–10:00 **PLENARY SESSION III**

HLA in Solid Organ Transplantation

PARALLEL SESSIONS

Great Auditorium

10:30–12:00 **Special Joint EFI-SIP Session**

Society for Immune Polymorphism: Advances in Clinical Immunogenomics

Room 300 *(Lower Foyer)*

10:30–12:00 **Teaching Session 3**

KIR immunogenetics & HLA epitopes: Mapping approaches & prediction methods

Auditorium 450 *(Upper Foyer)*

10:30–12:00 **Abstract Session 5: Bioinformatics, Data Analysis in Immunogenetics (O41-O48)**

Room 200 *(Upper Foyer)*

10:30–12:00 **Abstract Session 6: Immunotherapy, Gene Therapy, Cellular Therapy (O49-O56)**

Room 300 *(Lower Foyer)*

12:10–13:10 **Industry Symposium: GenDx**
13:20–14:20 **Industry Symposium: One Lambda Inc. a Thermo Fisher Scientific Brand**

Room J *(Upper Foyer)*

12:00–14:00 **SIP Board meeting**

Room G *(Upper Foyer)*

13:30–14:30 **EBTI GA**

Room 150 *(Lower Foyer)*

14:30–15:30 **Industry symposium: Omixon**

Auditorium 450 *(Upper Foyer)*

14:30–16:00 **Abstract Session 7: Hematopoietic Stem Cell Transplantation HSCT (O57-O64)**

Room 200 *(Upper Foyer)*

14:30–16:00 **Abstract Session 8: Autoimmunity, Infection, Reproduction & Cancer (O65-O72)**

Room 300 *(Lower Foyer)*

14:30–16:00 **Teaching Session 4**

Bioinformatics for Research Application

Great Auditorium	
14:30–16:00	Meet the Experts & Young EFI Group
Great Auditorium	
16:30–18:00	PLENARY SESSION IV
AI & Big data transforming medical research	
Great Auditorium	
18:00–19:30	EFI GENERAL ASSEMBLY
Les Machines de l'île	
21:00–23:00	Networking Event 1 / Conference Gala Dinner
Stereolux Club	
23:00–02:00	Networking Event 2 / After party

SATURDAY, April 29, 2023	
Great Auditorium	
08:30–10:00	Best Abstract Session (O1-O9)
10:30–12:00	PLENARY SESSION V
Autoimmune diseases & Infections	
12:00–13:30	CLOSING CEREMONY Closing Lecture IHIWS Best Abstract Awards Best Poster Awards



DETAILED PROGRAM

ASSOCIATED MEETINGS

TUESDAY, April 25, 2023

Room 150 *(Lower Foyer)*

09:00–17:15 **Inspectors Workshop**
Chairperson *Blanka Vidan-Jeras*

Rooms E & F *(Lower Foyer)*

08:30–17:30 **ESHI Diploma Examination**
Chairperson *David Turner*

WEDNESDAY, April 26, 2023

Room D *(Lower Foyer)*

08:30–16:30 **Executive Committee meeting**
Chairperson *Ann-Margaret Little*

Room E *(Lower Foyer)*

08:30–16:30 **External Proficiency Testing Committee meeting**
Chairperson *Helle Bruunsgaard*

Room F *(Lower Foyer)*

09:00–12:00 **IT & Bioinformatics Committee meeting**
Chairperson *Eric Spierings*

Room H *(Upper Foyer)*

08:30–17:00 **Accreditation Committee meeting**
Chairperson *Blanka Vidan-Jeras*

Room M *(Upper Foyer)*

08:30–16:30 **Standards Committee meeting**
Chairperson *Katy Latham*

Room I *(Upper Foyer)*

13:30–17:00 **Education Committee meeting**
Chairperson *Deborah Sage*

Room KL *(Upper Foyer)*

12:15–13:45	**Open Meeting of the Population Genetics Working Group**
Chairperson	*Alicia Sanchez-Mazas*
14:00–17:00	**Scientific Committee meeting**
Chairperson	*Luca Vago*

Room G *(Upper Foyer)*

14:30–16:30	**Young EFI Working Group**
Chairpersons	*Timo Olieslagers, Arianne Brandsma*

Journée scientifique de la Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI)

Auditorium 450 *(Upper Foyer)*

Chairperson	*SFHI Associated EFI Meeting*
13:30–14:15	**Quantification of allelic expression of HLA genes: methods, regulation, and implication in allograft** *Jean Villard*
14:15–15:00	**HLA and single-nucleotide polymorphisms: implication in diseases** *Nicolas Vince*
15:15–16:00	**B-lymphocytes function in chronic graft versus host disease** *Jonathan Visentin*
16:00–16:45	**Role of the transcriptional regulator BOB1 in immune tolerance and transplantation** *Nataliya Yeremenko*

WEDNESDAY, April 26, 2023

Great Auditorium

OPENING CEREMONY

17:30–18:00 **Welcome Addresses**
Pierre-Antoine Gourraud, Ann-Margaret Little

18:00–18:20 **Julia Bodmer Award**
Luca Vago

18:20–18:30 **HLA Award**
Steven Marsh

18:30–19:00 **Ceppellini Lecture**
Ann-Margaret Little

19:00–19:20 **Music by Conservatoire De Nantes – Special Opening**

Great Auditorium Foyer

19:30–21:00 **Welcome Cocktail**

THURSDAY, April 27, 2023

Great Auditorium

PLENARY SESSION I

Cell Therapies & Hematopoietic stem–cell transplantation

Chairpersons *Katharina Fleischhauer, Alexandre Walencik*

08:30–09:00 **How cell therapy has been implemented in Europe, evolution from classical to new therapies**
Florent Malard

09:00–09:30 **The graft-versus-host disease (GVHD): Novel developments in GVHD therapy**
Robert Zeiser

09:30–10:00 **Advancing T cell therapies (CAR T-cell immunotherapies)**
Carole Guillonneau

PARALLEL SESSIONS

Great Auditorium

Special Joint EFI–ESOT Session

The use of AI to Assist Decision Making in Transplantation

Chairpersons *Gilles Blancho, Kay Poulton*

10:30–11:00 **The ESOT initiative to build pan-European registries in SOT: why? how? where are we standing?**
Gabriel Oniscu

11:00–11:30 **The use of genomic to assist decision-making in transplantation**
Sophie Limou

11:30–12:00 **Refining the diagnosis of rejection by artificial intelligence**
Jasper Callemeyn

Room 300 *(Lower Foyer)*

Teaching Session 1

Innovation in Transplantation

Chairpersons	*Martijn van den Hoogen, Begoña Aran, Paul-Olivier Rouzaire*
10:30–11:00	**Telemedicine in renal transplantation: Innovations for 2023 and beyond** *Martijn van den Hoogen*
11:00–11:30	**Generation Of Human Induced Pluripotent Stem Cells From Haplo-Selected Cord Blood Samples (HAPLO-iPS)** *Begoña Aran*
11:30–12:00	**Temporal regulation of transgene expression controlled by amino acid availability in human T cells** *Paul-Olivier Rouzaire*

Auditorium 450 *(Upper Foyer)*

10:30–12:00	**Abstract Session 1: MHC Evolution, Population Genetics (O9-O16)**
Chairpersons	*Alicia Sanches-Mazas, Emmanuelle Génin*

Room 200 *(Upper Foyer)*

10:30–12:00	**Abstract Session 2: New Technologies & New Approaches in Immunogenetics (O17-O24)**
Chairpersons	*Florent Delbos, Silvia Gregori*

Room 300 *(Lower Foyer)*

12:10–13:10	**Industry Symposium: CareDx**
13:20–14:20	**Industry Symposium: Immucor**

Room G *(Upper Foyer)*

12:00–14:30	**EFI Executive Committee and Coordinators meeting**
Chairperson	*Ann-Margaret Little*

Room I *(Upper Foyer)*

13:30–14:30	**ETHIQ Diploma meeting**
Chairperson	*Deborah Sage*

Room J *(Upper Foyer)*

12:00–14:00	**SHLARC Consortium meeting**
Chairpersons	**Nicolas Vince, Pierre-Antoine Gourraud**

Great Auditorium

Special Joint EFI–NAT Session

Control of The Immune System in Transplantation

Chairpersons *Magali Giral, Jean Villard*

14:30–15:00 **Regulatory T cells, translation to the clinic**
Alberto Sanchez Fueyo

15:00–15:30 **Regulatory B cells, where are we?**
Mübeccel Akdis

15:30–16:00 **Regulatory B cells: A focus in Transplantation**
Sophie Hillion

Room 300 *(Lower Foyer)*

Teaching Session 2

Anthropology & Population Genetics: Immunogenetic diversity of the HLA system

Chairpersons *Emmanuelle Génin, Erick Castelli*

14:30–15:15 **Genetic diversity in metropolitan France at the beginning of the 20th century: the POPGEN project**
Emmanuelle Génin

15:15–16:00 **HLA genetic diversity and the challenges for analyzing highly polymorphic and repetitive genes**
Erick Castelli

Auditorium 450 *(Upper Foyer)*

14:30–16:00 **Abstract Session 3: NK Cells & KIR (O25-O32)**

Chairpersons *Danillo Augusto, Christelle Retière*

Room 200 *(Upper Foyer)*

14:30–16:00 **Abstract Session 4: Immunogenetics in Organ Transplantation (O33-O40)**

Chairpersons *Anat Tambur, Carole Guillonneau*

Great Auditorium

PLENARY SESSION II

HLA Immunogenetics, Population genetics & Evolution

Chairpersons *Lotte Wieten, Pierre-Antoine Gourraud*

16:30–17:00 **HLA and individual response to infection and vaccination**
Julian Knight

17:00–17:30 **Gene, transcript and proteins to understand immune diseases**
Patrick Sulem

17:30–18:00 **Illuminating the dark corners of the immune system: novel approaches for characterizing haplotype diversity in the T cell receptor and immunoglobulin loci**
Corey T Watson

***Mezzanine** (Upper Foyer)*

18:00–20:00	**Poster Viewing Session**
P1–P21	Autoimmunity, Infection, Reproduction & Cancer
P22–P43	Bioinformatics, Data Analysis in Immunogenetics
P44–P67	Hematopoietic Stem Cell Transplantation (HSCT)
P68–P82	Immunogenetics in Organ Transplantation
P83–P109	MHC Evolution, Population Genetics
P110–P117	NK cells & KIR
P118–P130	New Technologies & New Approaches in Immunogenetics

FRIDAY, April 28, 2023

Great Auditorium

PLENARY SESSION III

HLA in Solid Organ Transplantation

Chairpersons *Sebastiaan Heidt, Gwendaline Guidicelli*

08:30–09:00 **From HLA to MICA**
Seiamak Barham

09:00–09:30 **HLA molecular matching to improve transplant outcomes**
Anat Tambur

09:30–10:00 **Guiding pre-transplant desensitization and post-transplant DSA treatment**
Olga Timofeeva

PARALLEL SESSIONS

Great Auditorium

Special Joint EFI–SIP Session

Society for Immune Polymorphism: Advances in Clinical Immunogenomics

Chairpersons *Martin Maiers, Steven Mack*

10:30–11:00 **From Precision Microbial Genomics to Precision Medicine**
Ami Bhatt

11:00–11:30 **KIRs, T cell dynamics, control of chronic virus infection and autoimmunity**
Becca Asquith

11:30–12:00 **Immunogenetics of Hematopoietic Cell Transplantation**
Effie Petersdorf

***Room 300** (Lower Foyer)*

Teaching Session 3

KIR immunogenetics & HLA epitopes: Mapping approaches & prediction methods

Chairpersons *Christelle Retière, Eric Spierings*

10:30–11:15 **KIR immunogenetics and NK cell diversity**
Christelle Retière

11:15–12:00 **HLA epitopes and matching from a big data perspective**
Eric Spierings

Auditorium 450 *(Upper Foyer)*

10:30–12:00 **Abstract Session 5: Bioinformatics, Data Analysis in Immunogenetics (O41-O48)**

Chairpersons *Neema Mayor, Raphael Carapito*

Room 200 *(Upper Foyer)*

10:30–12:00 **Abstract Session 6: Immunotherapy, Gene Therapy, Cellular Therapy (O49-O56)**

Chairpersons *Pietro Crivello, Katia Gagne*

Room 300 *(Lower Foyer)*

12:10–13:10 **Industry Symposium: GenDx**

13:20–14:20 **Industry Symposium: One Lambda Inc. A Thermo Fisher Scientific Brand**

Room J *(Upper Foyer)*

12:00–14:00 **SIP Board meeting**

Chairpersons *Martin Maiers, Steven Mack*

Room G *(Upper Foyer)*

13:30–14:30 **EBTI GA**

Chairperson *David Turner*

Room 150 *(Lower Foyer)*

14:30–15:30 **Industry symposium: Omixon**

Auditorium 450 *(Upper Foyer)*

14:30–16:00 **Abstract Session 7: Hematopoietic Stem Cell Transplantation HSCT (O57-O64)**

Chairpersons *Valérie Dubois, Stephane Buhler*

Room 200 *(Upper Foyer)*

14:30–16:00 **Abstract Session 8: Autoimmunity, Infection, Reproduction & Cancer (O65-O72)**

Chairpersons *Régis Josien, Jill Hollenbach*

Room 300 *(Lower Foyer)*

Teaching Session 4

Bioinformatics for Research Application

Chairpersons *Yang Luo, Jean-Baptiste Woillard, Mathijs Groenewegen, Olivier Aubert*

14:30–15:00 **Pinpointing HLA selection signal in admixed populations**
Yang Luo

15:00–15:30 **Application of machine learning to prediction of immunosuppressant exposure, the example of Tacrolimus**
Jean-Baptiste Woillard

15:30–16:00 **Biomarkers and population stratification in Transplantation**
Olivier Aubert

Great Auditorium

14:30–16:00 **Meet the Experts & Young EFI Group**

Dominique Charron, Steven Marsh, Katharina Fleischhauer, Ronald Bontrop

Chairpersons *Timo Olieslagers, Arianne Brandsma*

Great Auditorium

PLENARY SESSION IV

AI & Big data transforming medical research

Chairpersons *Sophie Limou, James Robinson*

16:30–17:00 **Fine-mapping complex loci for autoimmune diseases**
Soumya Raychaudhuri

17:00–17:30 **Using transcriptome data to stratify and predict treatment responses in lupus and other systemic autoimmune diseases**
Marta Alarcón-Riquelme

17:30–18:00 **Using tissue and cell type-specific gene regulatory networks to predict driver genes of common diseases**
Patrick Deelen

Great Auditorium

18:00–19:30 **EFI GENERAL ASSEMBLY**

Agenda:

1. **Opening**
2. **Minutes of the General Assembly May 19, 2022 Amsterdam**
   (EFI Newsletter October 2022 Issue 98)
3. **Report of the EFI President**
4. **Report of the EFI Secretary**
5. **Report of the EFI Treasurer**
6. **Report of the EFI Committees**
   a) Accreditation
   b) Education
   c) External Proficiency Testing
   d) Scientific
   e) Standards and Quality Assurance
   f) IT & Bioinformatics Committee
7. **Next EFI Conference – Jerusalem, Israel 2024**
8. **EFI Medal**
9. **Installation of new EC members**

SATURDAY, April 29, 2023

Great Auditorium

08:30–10:00 **Best Abstract Session (O1-O9)**

Chairpersons *Luca Vago, Ann-Margaret Little*

PLENARY SESSION V

Autoimmune diseases & Infections

Chairpersons *Nicolas Vince, John Trowsdale*

10:30–11:00 **Infectious cause & Immunology of MS**
Marco Salvetti

11:00–11:30 **Repertoire profiling of adaptive immune responses against the human malaria parasite Plasmodium falciparum**
Hedda Wardemann

11:30–12:00 **Understanding immune diversity in health and disease**
Darragh Duffy

CLOSING CEREMONY

Chairpersons *Pierre-Antoine Gourraud, Ann-Margaret Little*

12:00–12:30 **Towards systems immunology? A philosophical perspective on the challenges of integrating Big Data and modeling**
Fridolin Gross

12:30–13:00 **IHIWS +365 Report**

Chairpersons *Sebastiaan Heidt, Eric Spierings*

Announcement about 19th IHIWS
Katsushi TOKUNAGA

13:00–13:15 **Jon Van Rood Award & Best Abstract Awards**

Committee Chair *Steven Marsh*

13:15–13:30 **Best Poster Awards**

Committee Chair *Nicolas Vince*

CLOSING REMARKS

CareDx®

AlloSeq Tx

Better Matching. Better Method.

THE NEXT GENERATION IN GENETIC MATCHING WITH INNOVATIVE HYBRID-CAPTURE TECHNOLOGY



Expandable Gene Content
without Affecting Lab Workflow

Easy Single Tube Workflow
with Early Indexing Step

No Long-range PCR =
No Amplification Inefficiencies

Fast Software Analysis
with Data Upload at 1 min/sample*

*as per internal testing



Availability

AlloSeq Tx9 (HLA-A, -B, -C, -DRB1/3/4/5, DQB1, DPB1) covers classical HLA loci

AlloSeq Tx17 (HLA-A, -B, -C, -E, -F, -G, -H, DRB1/3/4/5, DQA1, DQB1, DPA1, DPB1) moves beyond the traditional transplant related loci to consider more transplant associated genes

For more information visit **https://CareDx.com/AlloSeqTx** or reach out to your local CareDx representative.

MAR093 Revision 05 Effective 2023-03

NGS-TURBO®
HIGH-RESOLUTION HLA TYPING WITHIN 4 HOURS

Our new solution for nanopore HLA sequencing

- 11 loci whole gene
- Easy and robust workflow
- Nanopore sequencing
- Less than 4h turnaround time
- 1-tube library preparation
- Directly analyzed with NGSengine-Turbo



Contact sales@gendx.com and request a demo

experts in transplant diagnostics

GENDX

Yalelaan 48 | 3584 CM Utrecht | Utrecht Science Park
The Netherlands | +31 (0)30 252 3799 | www.GenDx.com

Seeing Beyond Limits

EVOLVE.

Looking for more solutions to help aid in your decision making process?

How could more tools in your toolbox better aid you in your decision making process for critical transplant patients? When you have more information at your disposal, you can optimise your decision making process for better efficiency and delivery of results. Make the best use of your valuable time by adding LIFECODES® Single Antigen Class I and Class II to your workflow.

SCAN to see how a fellow member of the HLA community accomplished this.

www.immucor.com

IMMUCOR

Software Automation

ThermoFisher SCIENTIFIC

HistoTrac™ Software

A comprehensive data management system for your HLA Laboratory

HistoTrac is a Laboratory Information Management System offered in modules to facilitate the building of a system that accommodates the testing services provided by your laboratory. The Core Package is the center of the software, providing for all the basic functions of the laboratory. Add modules, now or later, depending on your needs.

HistoTrac Software Configuration

HistoTrac software effectively manages HLA Laboratory workflow by:

- Sharing information with Reagent Vendor analysis software to complete test results.
- Sending automatic email transmission of NMDP donor confirmatory typings directly to the NMDP database.
- Managing the UNOS Wait List as well as updating unacceptable specificities via the UNET-specific API.
- Allowing remote access to patient data.



Information

- Patient/Donor Database
- Sample Registration
- Workflow Management
- Reporting

Innovation

- HistoTrac on the Web
- Paired Kidney Exchange
- DSA Analysis
- Virtual Crossmatch Assessment
- Eurotransplant Data Exchange

Integration

- HL7 Interfaces
  - ADT, Orders, Results, Billing
- Reagent Vendor Interfaces
  - Vendors for all methodologies are supported: Flow, Luminex, SSO, SSP, SBT, NGS, qPCR, STR
- HistoScope
- Organ Sharing Databases
- Bone Marrow Donor Databases

Services

- Data Conversion
- Custom Development and Reporting
- Training and Implementation Support

Visit us at EFI at booth #4

ONE LAMBDA
A Thermo Fisher Scientific Brand

LIST OF ORAL PRESENTATIONS

Abstract Session: MHC Evolution, Population Genetics (O9–O16)
Thursday, April 27, 10:30–12:00
Auditorium 450

O9/ID 5422
From global population genetic profiles to detailed individual molecular variation in humans and chimpanzees: a new turn in our understanding of MHC diversity and evolution
Alicia Sanchez-Mazas

O10/ID 3097
Creating fully representative MHC reference haplotypes
Nicholas R. Pollock

O11/ID 8033
MICA Copy Number Variations are the Result of Numerous Independent Non-Allelic Homologous Recombination Events
Anja Klussmeier

O12/ID 1551
Telomeres and ageing and their relation with HLA – results from the project "Immunogenetics of Ageing" within 18th IHIWS
Katarzyna Bogunia-Kubik

O13/ID 1600
Classical HLA alleles and long-range haplotypes are under rapid selection among admixed populations
Yang Luo

O14/ID 9773
Human Leukocyte Antigens (HLA) evolutionary divergence (HED) calculator
Bruno Lima

O15/ID 3186
A high-throughput approach to the MHC assembly challenge in disease association
Kristen J. Wade

O16/ID 6913
High Frequency of MICA Gene Deletion Haplotypes in Several Non-European Populations
Anja Klussmeier

New technologies & New Approaches in Immunogenetics (O17–O24)
Thursday, April 27, 10:30–12:00
Room 200

O17/ID 6210
The beneficial impact of HLA-E mismatching for patients receiving a less than 10/10 HLA matched hematopoietic cell transplant
Jonathan A.M. Lucas

O18/ID 4650
Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation
Pascal Pedini

O19/ID 685
Full-gene sequence characterization of HLA-DMA, -DMB, -DOA, and -DOB in a panel of International HLA and Immunogenetics Workshop cell lines
Matilda C. Tierney

O20/ID 5097
A randomized trial to assess the clinical utility of renal allograft monitoring by urine CXCL10 chemokine
Stefan Schaub

O21/ID 8439
Characterization of chimpanzee KIR haplotype organizations using Cas9 enrichment and Oxford Nanopore sequencing
Corrine Heijmans

O22/ID 757
TXMatching – a novel software for kidney paired donations
Matěj Röder

O23/ID 4379
HLA loss detection by NGS using STR markers within the MHC region on chromosome 6
Loes van de Pasch

O24/ID 4986
Assessment of a Universal Blood Donor Genotyping Platform
Colin Brown

Abstract Session: NK Cells & KIR (O25-O32)
Thursday, April 27, 14:30–16:00
Auditorium 450

O25/ID 3713
Chromosomal rearrangements in the KIR gene cluster as evolutionary strategy to protect against evading pathogens
Jesse Bruijnesteijn

O26/ID 7004
Variegated expression of KIR regulated by conserved and diverged promoter regions in humans and macaques
Marit van der Wiel

O27/ID 5716
Polymorphism of HLA and KIR affects severity of COVID-19 by shaping innate and adaptive immunity to SARS-CoV-2
Ticiana Dj Farias

O28/ID 9468
The role of natural killer cells in recurrent pregnancy loss: evaluation of natural killer cell education
Amber Lombardi

O29/ID 1207
KIR2DL2/C1: a potential predictive immunogenetic marker to COVID-19 severity in Spanish patients
Jairo Eduardo Niño Ramirez

O30/ID 9298
Nanopores may replace SMRT reads for dual redundant reference sequencing (DR2S): Characterization of more than 600 novel KIR alleles
Kathrin Putke

O31/ID 9873
Natural killer cell receptor variation is associated with more aggressive subtypes of breast cancer
Danillo Augusto

O32/ID 4161
HLA class I epitope and KIR diversities in multiple myeloma
Nicky Beelen

Abstract Session: Immunogenetics in Organ Transplantation (O33–O40)
Thursday, April 27, 14:30–16:00
Room 200

O33/ID 1424
Immunogenomic exploration in a large kidney transplantation genetic cohort reveals a kidney graft failure association with HLA-B*40:01 and KIRD2L2/HLA-C2 combination
Nicolas Vince

O34/ID 3470
In the era of precision medicine: lncRNAs as probable biomarkers to predict allograft rejection
Uma Kanga

O35/ID 1948
Gene expression profiles in 3-month biopsies associate with progression to kidney transplant rejection before detection of histological changes
Mathijs Groeneweg

O36/ID 2989
Precision medicine in liver transplant recipients: donor cell-free DNA as an early marker of post- transplant hepatic injury
Monica Sorbini

O37/ID 9184
Acute and chronic rejection monitoring of pediatric heart transplant recipients through a ddPCR assay based on HLA-DRB1 polymorphism
Monica Sorbini

O38/ID 6616
A genome-wide survival study identifies a novel association between donor genotype and antibody- mediated kidney graft rejection
Vincent Mauduit

O39/ID 4579
The number of donor HLA-derived T-cell epitopes available for indirect antigen presentation determines the risk for vascular rejection after kidney transplantation
Emma Peereboom

O40/ID 9981
Impact of HLA diversity on humoral response to SARS-Cov-2 and HBV vaccines in liver transplant recipients
Jean-Luc Taupin

Abstract Session: Bioinformatics, data analysis in Immunogenetics (O41–O48)
Friday, April 28, 10:30–12:00
Auditorium 450

O41/ID 848
Unexposed individuals are fully equipped at the genetic level in terms of peptide coverage and T-cell repertoire against SARS-CoV-2: analysis in a cohort of healthy donors and alloHSCT recipients
Stephane Buhler

O42/ID 1862
A new hla-mapper algorithm for alignment optimization of HLA sequences from RNA-seq
Erick Castelli

O43/ID 8886
HLA-3Diff: redefining donor-recipient HLA matching based on three dimensional structure prediction
Léo Boussamet

O44/ID 4733
Human Leucocyte Antigen variation is associated with Cytomegalovirus seropositivity
Juliano Boquett

O45/ID 4099
A large, improved and ancestry-diverse reference panel to impute HLA classical and non-classical class I alleles
Nayane S. B. Silva

O46/ID 8088
Possible Biological Mechanisms Underlying the Association between COVID-19 Severity and HLA- C*04:01
Frieda Jordan

O47/ID 9168
The expanded role of microRNAs in controlling the HLA class I phenotype: Relationship between the 3´ UTR and post-transcriptional Gene Regulation
Panagiotis Mallis

O48/ID 3787
Analysis of "Big Data" reveals a new MHC Class I sequence, HLA-OLI, and the location of HLA-Y
Lindley Blair

Abstract Session: Immunotherapy, Gene Therapy, Cellular Therapy (O49–O56)
Friday, April 28, 10:30–12:00
Room 200

O49/ID 3892
Polymorphic KIR3DL3 expression modulates tissue-resident and innate-like T cells
Paul Norman

O50/ID 7750
Memory CD4+ T cells efficiently recognize divergent HLA-DP immunopeptidomes relevant in allogeneic hematopoietic cell transplantation
Kulvara Kittissares

O51/ID 2944
Discovery of the human cytomegalovirus-specific peptide repertoire naturally processed and presented by infected human antigen presenting cells
Maria Michela Santamorena

O52/ID 4032
Exploring the cryptic HLA-DP immunopeptidome for new targets of T cell immunotherapy in acute myeloid leukemia
Pietro Crivello

O53/ID 5389
Generation and Characterization of third party donor derived AdV, CMV and EBV multivirus specific T cells for therapeutic intervention in patients undergoing Hematopoietic Stem Cell Transplantation
Meenakshi Singh

O54/ID 8869
Optimal population coverage for cellular therapies
Yoram Louzoun

O55/ID 5677
The stimulation of memory B cells for the identification of unacceptable antigens in solid organ transplantation
Linh Truong

O56/ID 8779
New regulatory dimensions for transplantation, genetics and stem cell research in the French bioethics law. Consequences for European collaborations
Anne Cambon-Thomsen

Abstract Session: Hematopoietic Stem Cell Transplantation (O57–O64)
Friday, April 28, 14:30–16:00
Auditorium 450

O57/ID 6533
HLA-DP permissive mismatch subsets confer reduced aGvHD risks and improved disease control after hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes
Esteban Arrieta Bolaños

O58/ID 873
T cells can be activated by epitopes presented on HLA-C*04:09N
Carlotta Welters

O59/ID 8963
Longitudinal tracking of T-cell receptor repertoire reconstitution after allogeneic hematopoietic stem cell transplantation
Antonia Schäfer

O60/ID 3205
Associations between HLA Evolutionary Divergence and clinical outcome of matched related or unrelated stem cell transplantation: a study from the EBMT Cellular Therapy and Immunobiology Working Party
Pietro Crivello

O61/ID 736
The role of Recipient Specific Antibodies (RSA) in transplant outcome. Analysis of a group of family donors selected for patients undergoing haploidentical transplantation
Annamaria Pasi

O62/ID 9591
HLA evolutionary divergence (HED) influences the outcome of haploidentical hematopoietic stem cell transplantation in adult patients with hematological malignancies
Debora Jorge Cordeiro

O63/ID 798
Combined imputation of HLA genotype and race leads to better donor-recipient matching
Yoram Louzoun

O64/ID 5359
Genetic variation in HLA genes: impact on transplant compatibility in a Brazilian admixed population
Heloísa S Andrade

Abstract Session: Autoimmunity, Infection, Reproduction & Cancer (O64–O72)
Friday, April 28, 14:30–16:00
Room 200

O65/ID 7848
A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited from Neanderthals in the Sardinian Population
Stefano Mocci

O66/ID 1174
HLA-A*03:01 significantly predicts strong humoral response at six months after mRNA vaccination: results from the observational prospective cohort study RENAISSANCE
Roberto Crocchiolo

O67/ID 7087
NEGR1 genetic variants and risk for virological failure in the HIV-positive Botswanan population
Martin Morin

O68/ID 2751
Copy number variation of the C4L gene isoform is associated with risk for multiple sclerosis
Jacqueline Williams

O69/ID 8515
HLA-E expression in HPV infected Cervical Carcinoma
Ritu Aggarwal

O70/ID 5590
HLA binding-groove motifs are associated with myocarditis induction after Pfizer-BioNTech BNT162b2 vaccination
Gil Benedek

O71/ID 7952
HLA-Bw4 is Associated with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)
Kerry Kizer

O72/ID 7171
Fight against COVID-19: functional and structural study of the T cell response
Stephanie Gras

Best Abstract Session (O1–O9)
Saturday, April 29, 08:30–10:00
Great Auditorium

O1/ID 4927
Forward or reversed binding of peptides within the HLA-DP peptidome is mainly determined by the HLA-DPB1 allele but with a key role for the HLA-DPA1 chain
Michel Kester

O2/ID 941
Single cell transcriptomics to identify leukemia-intrinsic and -extrinsic bone marrow correlates of immune escape and post-transplantation relapse
Marco Punta

O3/ID 6126
Highly specific Latent Membrane Protein 2A-targeting T-Cell Receptor-engineered T cells with inducible Interleukin-18 expression as promising tool to treat Epstein-Barr Virus-associated malignancies
Philip Mausberg

O4/ID 7583
Proteome analysis of drug susceptible HLA-B*57:01+ cells reveals the pivotal mechanisms of HLA- mediated Carbamazepine hypersensitivity
Funmilola Josephine Haukamp

O5/ID 2276
The evolution of MHC class I loss in a newly emerged transmissible cancer in Tasmanian devils
Kathryn Hussey

O6/ID 1570
Bw4 ligand and direct T-cell receptor binding induced selection on HLA-A and -B alleles
Yoram Louzoun

O7/ID 6775
The 18th International HLA and Immunogenetics Workshop (IHIWS) HLA immunogenic epitope project
Cynthia Kramer

O8/ID 9702
Spatial composition of decidual immune cells in oocyte donation pregnancies in relation to fetal- maternal HLA incompatibility
Xuezi Tian

LIST OF POSTERS

Autoimmunity, Infection, Reproduction & Cancer

P1/ID 2158

T cell receptor beta gene diversity identified by Next Generation Sequencing in Chronic Myeloid Leukemia patients

Gurvinder Kaur[1], Ayushi Jain[1], Kamaljeet Singh[1], Rahul Ahuja[1], Lingaraja Jena[1], Indresh K Singh[1], Pramod K Verma[1], Sangita Vashishtha[1], Vikas Bisht[1], Deepshi Thakral[1], Ranjit K Sahoo[2], Atul Sharma[2], Lalit Kumar[2] and Ritu Gupta[1]

[1]Laboratory Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, India, [2]Medical Oncology, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi, India

P2/ID 3723

HLA class I immune editing in JAK2 V617F and CALR exon 9 mutation driven myeloproliferative malignancies

Milena Ivanova[1], Gergana Tsvetkova[2], Iliana Micheva[3], Spaska Lessichkova[1], Zasmina Petrova[4], Anela Ivanova[4], Galja Madjarova[4], Evgueniy Hadjiev[2] and Velizar Shivarov[5]

[1]Department of Clinical Immunology, University Hospital Alexandrovska, Medical University, Sofia, Bulgaria, [2]Department of Clinical Hematology, University Hospital Alexandrovska, Medical University, Sofia, Bulgaria, [3]Clinic of Hematology, University Hospital Sveta Marina, Medical University, Varna, Bulgaria, [4]Department of Physical Chemistry, Faculty of Chemistry and Pharmacy, Sofia University "St. Kl. Ohridski", [5]Department of Experimental Research, Medical University Pleven, Bulgaria

P3/ID 4664

Humoral response against SARS-CoV-2 and other endemic corona viruses

Karla Rottmayer[1], Ramona Landgraf[1], Nicole Lakowa[2], Thomas Grünewald[2], Ilias Doxiadis[1] and Claudia Lehmann[1]

[1]University Hospital Leipzig, Transfusion Medicine, Transplantation Immunology,Germany, [2]Klinikum Chemnitz gGmbH, Infection and Tropical Medicine, Germany

P4/ID 7272

Diverse data in multiple sclerosis improves machine learning performance to predict the short-term evolution of disability: lessons from the EPIC cohort

Antoine Lizée[1], Stanislas Demuth[2], Adam Santaniello[1], Bruce Cree[1], Jorge Oksenberg[1], Stephen Hauser[1], Sergio Baranzini[1], Riley Bove[1] and Pierre-Antoine Gourraud[2]

[1]Department of Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA, United States, [2]Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France

P5/ID 725

PRIMUS-Alpha: a clinical decision support system prototype for precision medicine in multiple sclerosis contextualizing patients' evolutions in multi-source reference data

Stanislas Demuth[1], Chadia Ed-Driouch[1], Olivia Rousseau[1], Romain Casey[2], Alexandra Auffret[3], Marianne Payet[4], Jérôme De Sèze[5], David Laplaud[1], Gilles Edan[6], Pierre-Antoine Gourraud[1] and Primus Consortium[7]

[1]Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000 Nantes, France, [2] French Multiple Sclerosis Observatory, Lyon university hospital, Lyon, France, [3] Biogen France S.A.S, Paris, France, [4] Neurology, Merck Santé S.A.S, Lyon, France, [5] Department of neurology, Strasbourg university hospital, Strasbourg, France, [6] Department of neurology, Rennes university hospital, Rennes, France, [7]PRIMUS consortium

P6/ID 3182

HNA antibody association to HLA alleles and autoimmune neutropenia

Kirstine Kløve-Mogensen[1], Rudi Steffensen[1], Tania Nicole Masmas[2], Andreas Glenthøj[2], Thure Mors Haunstrup[1], Paul Ratcliffe[3], Petter Höglund[3], Henrik Hasle[4] and Kaspar René Nielsen[1]

[1]Aalborg University Hospital, Denmark, [2]Copenhagen University Hospital, Denmark, [3]Karolinska Institute, Sweden, [4]Aarhus University Hospital, Demark

P7/ID 2013

Association between T regulatory cell genes and autoimmune neutropenia

Kirstine Kløve-Mogensen[1], Rudi Steffensen[1], Tania Nicole Masmas[2], Andreas Glenthøj[2], Thure Mors Haunstrup[1], Paul Ratcliffe[3], Petter Höglund[3], Henrik Hasle[4] and Kaspar René Nielsen[1]

[1]Aalborg University Hospital, Denmark, [2]Copenhagen University Hospital, Denmark, [3]Karolinska Institute, Sweden, [4]Aarhus University Hospital, Denmark

P8/ID 1143

Impact of HLA class U and class II on malignancies driven by BRCA1 mutation

Milena Ivanova[1], Anastasia Ormandjieva[1], Rumyana Dodova[2], Radka Kaneva[2] and Velizar Shivarov[3]

[1]Department of Clinical Immunology, University Hospital Alexandrovska, Medical University Sofia, Bulgaria, [2]Molecular Medicine Center, Medical University Sofia, Bulgaria [3]Department of Experimental Research, Medical University Pleven, Bulgaria

P9/ID 923

HLA allele association studies with the kinetics of SARS-CoV-2 spike protein-specific IgG antibody responses to BNT162b2 mRNA vaccine

Seik-Soon Khor[1], Yosuke Omae[1], Junko S. Takeuchi[2], Ami Fukunaga[3], Shohei Yamamoto[3], Akihito Tanaka[4], Kouki Matsuda[5], Moto Kimura[2], Kenji Maeda[5], Gohzoh Ueda[6], Tetsuya Mizoue[3], Mugen Ujiie[7], Hiroaki Mitsuya[5], Norio Ohmagari[7], Wataru Sugiura[8] and Katsushi Tokunaga[1]

[1]Genome Medical Science Project, National Center for Global Health and Medicine, Tokyo, Japan, [2]Department of Academic-Industrial Partnerships Promotion, Centre for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan [3]Department of Epidemiology and Prevention, Centre for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, [4]Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan, [5] Department of Refractory Viral Infection, National Center for Global Health and Medicine, Tokyo, Japan, [6]Division of Core Diagnostics, Abbott Japan LLC, Tokyo, Japan, [7] Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan, [8] Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

P10/ID 2921

Single Nucleotide Variation, associated Human Leukocyte Antigen and Cytokines as possible biomarkers in the diagnosis of Psoriasis patients in Tshwane, South Africa

Mkhize Nomzamo[1], Kgokolo Mahlatse[1], Steel Helen[2], Meyer Pieter[2,3], Kwofie Luyanda[2,3]

[1]Department of Dermatology, School of Medicine, Faculty of Health Sciences, University of Pretoria and Steve Biko Academic Hospital, Pretoria, South Africa, [2]Department of Immunology, School of Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa, [3]Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South Africa

P11/ID 5558

Exploring genetic predisposition towards manifestation of Oral Submucous Fibrosis among tobacco consuming North Indians

Uma Kanga[1], Bharathi Purohit[2], Harsh Priya[2], Ritu Duggal[3] and Shalini Gupta[4]

[1]Dept of Transplant Immunology and Immunogenetics, All India Institute of Medical Sciences, New Delhi New Delhi, India, [2]Division of Public Health Dentistry, CDER, AIIMS, New Delhi, India, [3]Division of Orthodontics CDER AIIMS New Delhi, India, [4]Division of Oral Medicine & Radiology CDER AIIMS New Delhi, India

P12/ID 4433

Analysis of Human Leukocyte Antigen HLA surface expression and the tumor microenvironment in Hodgkin lymphoma as a potential tumor immune escape mechanism in Egyptian patients

Mariam Ayoub[1]

[1]German University in Cairo, Egypt

P13/ID 1325

HLA alleles and SNPs association study with HBV-related liver cirrhosis and hepatocellular carcinoma in a Greek population

Evangelia Myserli[1], Georgia Gioula[1], Grigorios Myserlis[2], Aliki Xochelli[3], Anna Boukla[3], Evangelia Sidira[3], Ioannis Goulis[4] and Asimina Fylaktou[3]

[1]Microbiology Department, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece, [2]Division of Transplantation, Department of Surgery, Aristotle University Medical School, Hippokration General Hospital of Thessaloniki, Thessaloniki , Greece, [3]National Peripheral Histocompatibility Center, Immunology department, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece, [4]4th Department of Internal Medicine, Medical school of Aristotle University, Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece

P14/ID 9548

HLA variants associated with sarcoidosis and their tag single nucleotide polymorphisms in Czechs

Kateřina Sikorová[1], Martina Doubková[2], Adam Strnad[1], Lenka Kocourková[1], Jana Petřková[1], Kazutoyo Osoegawa[3], Marcelo A. Fernández-Viña[4] and Martin Petrek[5,6]

[1]Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic, [2]Department of Pulmonary Diseases & Tuberculosis, University Hospital Brno, and Faculty of Medicine Masaryk University, Brno, Czech Republic, [3]Histocompatibility & Immunogenetics Laboratory, Stanford Blood Center, Palo Alto, USA [4]Histocompatibility, Immunogenetics, and Disease Profiling Laboratory, Stanford Blood Center and Department of Pathology, Stanford Blood Center, Palo Alto, USA, [5]University Hospital Olomouc, Cardiogenomics LEM, Olomouc, Czech Republic, [6]Department of Pathological Physiology and Institute of Molecular & Translational Medicine, Faculty of Medicine and Dentistry, Olomouc, Czech Republic

P15/ID 3395

Immunogenetics and SARS-CoV-2 infection

Claudia Lehmann[1], Henry Loeffler-Wirth[2], Vera Balz[3], Juergen Enczmann[3], Ramona Landgraf[1], Nicole Lakowa[4], Thomas Grünewald[4], Johannes Fischer[3] and Ilias Doxiadis[1]

[1]University Hospital Leipzig, Transfusion Medicine, Transplantation Immunology, Leipzig, Germany [2]IZBI, Interdisciplinary Centre for Bioinformatics, Leipzig University, Leipzig, Germany [3]University Hospital Duesseldorf, ITZ, HLA Laboratory, Duesseldorf, Germany [4]Klinikum Chemnitz gGmbH, Infection and tropical medicine, Chemnitz, Germany

P16/ID 5914

Role of HLA polymorphism in COVID-19 progression in the Bulgarian population

Tsvetelin Lukanov[1], Bushra Al Hadra[2], Snezhina Kandilarova[1], Zulieta Hristova[3], Yulia Proevska[4], Evelina Shikova[4], Spaska Lesichkova[1], Nedelcho Ivanov[2], Atanaska Georgieva[2], Daniela Lalova[2], Tsvetan Popov[5], Dobrin Svinarov[6], Anastasiya Mihaylova[2] and Elisaveta Naumova[3]

[1]Department of Clinical Immunology, Medical University Sofia, Sofia, Bulgaria, [2]Clinic of Clinical Immunology and Stem Cell Bank, University Hospital Alexandrovska, Sofia, Bulgaria, [3]Department of Clinical Laboratory, Medical University Sofia, Sofia, Bulgaria, [4]Department of Microbiology, University Hospital Alexandrovska, Sofia, Bulgaria [5]General Surgery, University Hospital Alexandrovska, Sofia, Bulgaria [6]Clinical Pharmacology, University Hospital Alexandrovska, Sofia, Bulgaria

P17/ID 1675

Association of TLR10 single nucleotide polymorphisms with hidradenitis suppurativa in a Caucasian Spanish population cohort

Adriel Roa-Bautista[1], J. Gonzalo Ocejo-Vinyals[1], Elena González-López[1], Juan Irure-Ventura[1], Miguel Angel González-Gay[2], Ricardo Blanco[2] and Marcos Antonio González-López[3]

[1]Division of Immunology, Hospital Universitario Marqués de Valdecilla, Santander, University of Cantabria, IDIVAL, Cantabria, Spain, [2]Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Cantabria, Spain, [3]Division of Dermatology, Hospital Universitario Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Cantabria, Spain

P18/ID 7606

Haplotype frequencies and linkage disequilibrium between HLA*DRB1 and SNP -197 of IL-17 in Russian patients with rheumatoid arthritis living in Chelyabinsk region

Daria Stashkevich[1], Daria Shmelkova[1], Elena Khromova[1], Inessa Devald[1], Tatiana Suslova[2] and Alexandra Burmistrova[1]

[1]Chelyabinsk State University, Russia, [2]Chelyabinsk State University, Chelyabinsk Blood Transfusion Station, Russia

P19/ID 5887

Distribution of HLA-B alleles among Human Immunodeficiency Virus-1 Infected Turkish Adults

Servet Uluer Biceroglu[1], Husnu Pullukcu[2], Semiha Ozgul[3], Gulsen Mermut[2], Ayhan Donmez[1] and Deniz Gokengin[2]

[1]Ege University Faculty of Medicine Tissue Typing Laboratory, Izmır, Turkey, [2]Ege University Faculty of Medicine Department of Infectious Diseases and Clinical Microbiology, Izmır, Turkey, [3]Ege University Faculty of Medicine Department of Biostatistics and Medical Informatics, Izmır, Turkey

P20/ID 3321

TNFRSF11B gene polymorphism in Russian patients with rheumatoid arthritis living in Chelyabinsk region

Julia Chumacheva[1], Daria Stashkevich[1], Tatiana Suslova[1] and Alexandra Burmistrova[1]

[1]Chelyabinsk State University, Chelyabinsk, Russia

P21/ID 3705

The Frequency of HLA-A, -B, -C, -DRB1 and -DQB1 alleles in Patients with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia

Bilkay Basturk[1,2], Miray Kavuzlu[2] and Mutlu Kasar[3]

[1]Baskent University Faculty of Medicine, Department of Immunology, Adana, Turkey, [2]Baskent University Dr Turgut Noyan Research and Medical Center Immunology and Tissue typing Lab, HLA Lab, Adana, Turkey, [3]Baskent University Faculty of Medicine Department of Internal Medicine/Hematology Adana, Turkey

Bioinformatics, data analysis in Immunogenetics

P22/ID 1335

HLA-A*03:01 is associated with systemic side effects in COVID-19 vaccination

Anshika Srivastava[1], Tasneem Yusufali[1], Noah D. Peyser[2], Gregory M. Marcus[2], Jeffrey E. Olgin[2], Mark J. Pletcher[3], Martin Maiers[4] and Jill A. Hollenbach[1]

[1]Department of Neurology, University of California, San Francisco, CA, USA, [2]Department of Medicine, University of California, San Francisco, CA, USA, [3]Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA, [4]National Marrow Donor Program, Minneapolis, MN, USA

P23/ID 5340

Attention Based Immune Repertoire Classification

Ofek Akerman[1], Reut Levi[1] and Yoram Louzoun[1]

[1]Department of Mathematics, Bar Ilan University, Ramat Gan, Israel

P24/ ID 3609

Statistical inference of immunogenetic parameters reveals an HLA allele associated with pediatric proteinuria

Axelle Durand[1], Cheryl A. Winkler[2], Nicolas Vince[1], Derek K NG[3], Elizabeth Binns-Roemer[2], Pierre-Antoine Gourraud[1], Bradley Warady[4], Kimberley Reidy[5], Susan Furth[6], Jeffrey B. Kopp[7], Frederick J. Kaskel[5] and Sophie Limou[1]

[1]Nantes Université, CHU Nantes, Ecole Centrale de Nantes, INSERM, CR2TI, Nantes, France, [2]Basic Research Laboratory, Center for Cancer Research, NCI, Frederick National Laboratory, Frederick, MD, USA [3]Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, [4]Children's Mercy Kansas City, Kansas City, MO, USA, [5]Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA 6 NIDDK, NIH, Bethesda MD, USA, [6]Children's Hospital of Pennsylvania, Philadelphia, PA, USA [7]Kidney Disease Section NIDDK, NIH, Bethesda, MD, USA.

P25/ID 4818

SHLARC imputation server: HLA imputation from SNPs made easy with a new website and a large reference panel

Sonia Bourguiba-Hachemi[1], Nayane S. B. Silva[1], Venceslas Douillard[1], Pierre-Antoine Gourraud[1], Sophie Limou[1] and Nicolas Vince[1]

[1]Nantes Université, INSERM, Ecole Centrale Nantes, CHU Nantes, CR2TI, UMR 1064, Nantes, France

P26/ID 3657

Nanopore sequencing data analysis using a cloud computing service

Linh Truong[1,2], Felipe Ayora[3], Lloyd D'Orsogna[1,2], Patricia Martinez[1,2] and Dianne De Santis[1,2]

[1]UWA Medical School, UWA, Perth, Australia, [2]Clinical Immunology, PathWest, Fiona Stanley Hospital, Perth, Australia, [3]BizData, Wellington, New Zealand

P27/ID 348

GRMA – Graph based HLA-matching with mismatches

Amit Kabya[1], Sapir Israeli[1], Martin Maiers[2] and Yoram Louzoun[1]

[1]Department of Mathematics, Bar Ilan University, Ramat Gan, Israel, [2]National Marrow Donor Program, Minneapolis, MN, USA

P28/ID 8982

Kidney transplantation follow-up: personalized patient contextualization with a nearest neighbor approach

Olivia Rousseau[1], Estelle Geffard[1], Axelle Durand[1], Magali Giral[2], Alexandre Loupy[3], Sophie Brouard[1], Carmen Lefaucheur[4], Emmanuel Morelon[5], Lionel Couzi[6], Nassim Kamar[7], Moglie Le Quintrec[8], Nicolas Vince[1], Sophie Limou[1], Pierre-Antoine Gourraud[1], RHU KTD-Innov Consortium[9] and DIVAT Consortium[10]

[1]Nantes Université, INSERM, Ecole Centrale Nantes, CHU Nantes, CR2TI, UMR 1064, Nantes, France, [2]CHU de Nantes, Nantes, France, [3]Paris Translational Research Center for Organ Transplantation, Paris , France, [4]Assistance Publique-Hôpitaux de Paris, Paris, France, [5]Université de Lyon Service de néphrologie, Lyon, France, [6]CHU de Bordeaux, Bordeaux, France, [7]CHU de Toulouse, Toulouse, France, [8]CHU de Montpellier, Montpellier, France, [9]RHU KTD-Innov consortium, [10]DIVAT Consortium

P29/ID 6803

HLA-net interactive interface: making big data small and accessible

Enrique Alanis[1], David Roessli[1], Jose Manuel Nunes[1] and Da Di[1]

[1]Anthropology Unit, Department of Genetics and Evolution, University of Geneva, Geneva, Switzerland

P30/ID 3195

A large French genetic cohort to identify predictive molecular factors of chronic lung allograft dysfunction

Simon Brocard[1], Martin Morin[1], Axelle Durand[1], Pierre-Antoine Gourraud[1], Mario Sudholt[2,3], Adrien Tissot[1] and Sophie Limou[1]

[1]Nantes Université, CHU Nantes, Centrale Nantes, Inserm, CR2TI, UMR 1064, ITUN, Nantes, France, [2]IMT Atlantique – DAPI – Département Automatique, Productique et Informatique, Nantes, France, [3]LS2N – STACK – Software Stack for Massively Geo-Distributed Infrastructures, Nantes, France

P31/ID 5347

Protection of HLA-A and HLA-B epitopes in the context of platelet transfusions in haplo-identical hematopoietic stem cell allograft candidates

Gatien Durand[1], Corinne Lorriaux[2], Géraldine Poumaredes[3], Judith Desoutter[1] and Nicolas Guillaume[1]

[1]Laboratory of Histocompatibility – Amiens University Medical Center, Amiens, France, [2]Hemovigilance Department – Amiens, France, [3]Etablissement Français du Sang (EFS) – Amiens, France

P32/ID 129

Defining and confirming novel HLA serological specificities from combinational analyses of single antigen bead and cell-based flow crossmatch assays

Kazutoyo Osoegawa[1], Lin Wang[1], Ketevan Gendzekhadze[2], Cathi Murphey[3] and Marcelo A. Fernández Viña[4]

[1]Histocompatibility and Immunogenetics Laboratory, Stanford Blood Center, Palo Alto CA, USA, [2]HLA Laboratory City of Hope, [3]Histocompatibility and Immunogenetics Laboratory at Southwest Immunodiagnostics, Inc San Antonio, TX, USA, [4]Department of Pathology, Stanford University School of Medicine, Palo Alto CA, USA

P33/ID 800

Significantly different HLA genotypes associations with multiple sclerosis suggest different pathophysiological underlying mechanisms

Anna Serova-Erard[1], Sonia Bourguiba-Hachemi[1], Pierre-Antoine Gourraud[1], Nicolas Vince[1] and François Cornelis[1]

[1]Nantes Université, CHU Nantes, Inserm, CR2TI, UMR 1064, Nantes, France

P34/ID 9693

Data sharing, research evaluation and Open Science

Mogens Thomsen[1], Florencia Grattarola[2], Hanna Shmagun[3], Chris Erdmann[4], Laurence Mabile[5] and Anne Cambon-Thomsen[6]

[1]CERPOP, INSERM and Université de Toulouse III Paul Sabatier, Toulouse, France, [2]Biodiversidata, Uruguay, [3]Korea Institute of Science and Technology Information, Korea, [4]Michael J. Fox Foundation, New York, USA, [5]INSERM and Université de Toulouse III Paul Sabatier, Toulouse, France, [6]CNRS and Université de Toulouse III Paul Sabatier, Toulouse, France

P35/ID 7926

A retrospective study; Effect of sensitization events on anti-HLA antibody development

Rasime Derya Güleç[1] and Fatma Demet Arslan[2]

[1]Tepecik Training and Research Hospital Tissue Typing Laboratory, Izmir, Turkey, [2]Faculty of Medicine, Bakırçay University, Department of Medical Biochemistry, Izmir, Turkey

P36/ID 9410

A research tool to interrogate combined single antigen bead (SAB) files with donor and recipient HLA typing information to identify HLA mismatches and MFI levels of donor specific antibodies over time. Introducing the mismatch data aggregator (MDA) program

Rebecca Cope[1], Rhea McArdle[2], Afzal Chaudhry[1] and Sarah Peacock[1]

[1]Cambridge University Hospital NHS Foundation Trust, UK, [2]University Hospitals Leicester, Leicester, UK

P37/ID 7674

Reshaping individuals' rights in Big Data research: the contribution of data altruism

Emmanuelle Rial-Sebbag[1], Noémie Dubruel[2], Lisa Fériol[1] and Gauthier Chassang[1]

[1]CERPOP, INSERM and Université de Toulouse III Paul Sabatier, Toulouse, France, [2]INSERM and Université Toulouse Capitole, Toulouse, France

P38/ID 9159

A comprehensive statistical analysis to assess MFI values in HLA antibody screening by two commercial platforms

Giovanni Rombolà[1], Antonina Piazza[2], Maria Chiara De Stefano[2], Dario Ciappi[1], Sara Iozzi[1] and Elisabetta Pelo[1]

[1]Immunogenetica, SOD Diagnostica Genetica, AOU Careggi, Florence, Italy, [2]Commissione Controlli Qualità, Centro Nazionale Trapianti, Rome, Italy

P39/ID 1744

Work smarter not harder! A clinical tool to combine single antigen bead (SAB) files for patients allowing for data to be easily viewed and analyzed in the clinical laboratory. Introducing the SAB Combiner (SC) program

Rebecca Cope[1], Rhea McArdle[1], Afzal Chaudhry[1] and Sarah Peacock[1]

[1]Cambridge University Hospital NHS Foundation Trust, Cambridge, UK

P40/ID 8919

Advyser solid organs software for accurate post transplantation monitoring

Julia Paschke[1] and Hamid Ramezanalli[1]

[1]Devyser AB, Stockholm, Sweden

P41/ID 1061

HLA-A~B~DRB1-DQB1 homozygosity among the Brazilian Bone Marrow Registry living in Rio de Janeiro State, Brazil

Danielle Secco[1], Tais Kasai-Brunswick[2,3,4], Jeane de Souza[1], Juliana Pessanha[1], Danielli Cristina Oliveira[5], Leandro Guimarães[5], Marcio Lassance[4], Antônio Carlos Campos de Carvalho[2,3,4] and Luis Cristovao Porto[1]

[1]Laboratório de Histocompatibilidade e Criopreservação, Universidade Estadual do Rio de Janeiro- UERJ, Rio de Janeiro, Brasil, [2]Centro Nacional de Biologia Estrutural e Bioimagem – CENABIO, Universidade Federal do Rio de Janeiro – UFRJ, Rio de Janeiro, Brasil, [3]Instituto de Biofísica Carlos Chagas Filho – IBCCF, Universidade Federal do Rio de Janeiro –UFRJ, Rio de Janeiro, Brasil, [4]Instituto Nacional de Cardiologia – INC, Rio de Janeiro, Brasil, [5]Registro Brasileiro de Doadores de Medula Óssea – REDOME, Instituto Nacional do Câncer -INCA, Rio de Janeiro, Brasil

P42/1467

Comparison of Kit Use and Performance in UK NEQAS for H&I Scheme 3 – HLA Antibody Specificity Analysis

Amy De'Ath[1], Geraint Clarke[1], Deborah Pritchard[1] and Tracey Rees[2]

[1]UK National External Quality Assessment Service for Histocompatibility and Immunogenetics, UK, [2]Welsh Blood Service, UK

P43/3737

An HLA-DRB1*03:105 allele in a patient awaiting a kidney donor in Colombia

Juan Yunis[1], Mayorie Dakkak[1], Adriana Chamorro[1], Natalia Arias[1], Jhon Rodriguez[1] and Alexandra Cortez[1]

[1]Servicios Médicos Yunis Turbay y Cia SAS-Instituto de Genética, Bogotá, D.C. Colombia

P44/ID 412

NK cell licensing effect is independent of missing KIR ligand effect in T cell-replate unrelated hematopoietic stem cell transplantation for malignant diseases

Jacek Nowak[1], Agnieszka Witkowska[1], Marta Rogatko-Koroś[1], Agnieszka Malinowska[1], Elżbieta Graczyk-Pol[1], Anna Flaga[1], Urszula Szlendak[1], Anna Wnorowska[1] and Agnieszka Gawron[1]

[1]Department of Immunogenetics, Institute of Hematology and Transfusion Medicine, Warsaw, Poland

P45/ID 1781

Plasma cell-directed therapy and anti-HLA antibody synthesis: results from a prospective observational study

Martina Soldarini[1], Anna Maria Cafro[1], Paola Bertazzoni[1], Maria Luisa Pioltelli[1], Giorgia Cornacchini[1], Giuliana Lando[1], Elisabetta Sommaruga[1], Antonio Milano[1], Roberto Cairoli[1], Silvano Rossini[1] and Roberto Crocchiolo[1]

[1]ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

P46/ID 7547

Microchimerism levels of recipient cells: frequency and impact on hematopoietic stem cell transplantation outcome

Katarina Stingl Jankovic[1], Marija Maskalan[1], Marija Burek Kamenaric[1], Mirta Mikulic[2], Lana Desnica[2], Nadira Durakovic[2], Ranka Serventi-Seiwerth[2], Radovan Vrhovac[2], Renata Zunec[1] and Zorana Grubic[1]

[1]Tissue Typing Centre, University Hospital Centre Zagreb, Zagreb, Croatia, [2]Division of Hematology, University Hospital Center Zagreb, Zagreb, Croatia

P47/ID 8496

Facilitation of stem cell transplantation in a highly sensitized AML patient through Imlifidase treatment

Sharon Vivers[1,2], Raymond Fernando[3], Sandra Frater[1], Maya Knox-Macaulay[4], Franco Tavarozzi[1] and Lisa Walsh[1]

[1]Anthony Nolan Histocompatibility Laboratories, London, UK, [2]UCL Cancer Institute, UCL Campus, London, UK, [3]Solid Organ Group, Anthony Nolan, Royal Free Hospital, London, UK, [4]Anthony Nolan, London, UK

P48/ID 6974

Comparison of two methodologies for monitoring chimerism after allogeneic stem-cell transplantation: Next-Generation Sequencing (NGS) vs. Short-Tandem Repeats (STR)

Jairo Niño-Ramírez[1], Alejandro Medina[1], Estrella Arnés-Moreta[1], Ana Balanzategui[1], Rocío Corral[1], Alicia Antón[1], María García-Álvarez[1], Rebeca Maldonado[1], Miguel Bastos-Boente[1], Igor de la Torre[1], Nerea H. Vidaña[1], Cristina Jiménez[1], María Eugenia Sarasquete[1], M. Carmen Chillón[1], Montserrat Hernández-Ruano[1], Sandra M. Lucas[1], Ana Isabel Sánchez-González[1], Inmaculada Sánchez-Villares[1], Verónica González-Calle[1], Almudena Navarro-Bailón[1], Francisco Boix[1], F. Javier Gil-Etayo[1], Amalia Tejeda-Velarde[1], Ramón García-Sanz[1] and Miguel Alcoceba[1]

[1]Department of Hematology, Hospital Universitario de Salamanca-IBSAL, CCIC-IBMCC (USAL-CSIC) and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Spain

P49/ID 6587

Loss of mismatched HLA haplotype after haplo-identical hematopoietic stem cell transplantation relapse

Dario Merlo[1], Sandra Frater[1], James Peat[1], Zdenka Edwards[1], Sharon Vivers[1] and Lisa Walsh[1]

[1]Anthony Nolan Research Institute, Royal Free Hospital, London UK

P50/ID 8003

Detection of HLA Antibodies in potential haploidentical HSC transplant recipients

Natalia Ivanova[1], Irina Pavlova[2], Vera Khvoshch[1], Anna Nasredinova[1], Veronika Ermolina[1], Svetlana Typushkina[1], Svetlana Merzlykova[1] and Alexander Kulagin[1]

[1]Raisa Gorbacheva Memorial Inst. for Pediatric Oncology, Hematology and Transplantation, Saint Petersburg, Russia, [2]Russian Institute of Hematology, Raisa Gorbacheva Memorial Inst. for Pediatric Oncology, Hematology and Transplantation, Saint Petersburg, Russia

P51/ID 5022

Assessment of Chimerism by Next Generation Sequencing: A Comparison to STR-PCR method

Darren Brow[1], Jasmine Kendrick[1], David Viswanatha[2], Mohamed Kharfan Dabaja[3] and Mohamed Elrefaei[1]

[1]Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA, [2]Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, MN, USA, [3]Department of Hematology Oncology, Mayo Clinic Jacksonville, FL, USA

P52/ID 3828

Chimerism analysis using next generation sequencing

Sara Iozzi[1], Dario Ciappi[1], Simona Palchetti[1], Ugo Ricci[1], Giovanni Rombolà[1] and Elisabetta Pelo[1]

[1]SOD Diagnostica Genetica, AOU Careggi, Florence, Italy

P53/ID 1995

Non-malignant hematological diseases treated by haploidentical hematopoietic stem cell transplantation: anti-HLA antibodies and graft failure

Paola Giustiniani[1], Federica Galaverna[2], Pietro Merli[2], Antonio Giuseppe Bianculli[1], Marco Becilli[2], Roberto Carta[2], Emilia Boccieri[2], Maria Troiano[1], Rita Maria Pinto[2], Mariarosa Battarra[1], Marco Andreani[1] and Franco Locatelli[2,3]

[1]Laboratorio di Immunogenetica dei Trapianti, Ospedale Pediatrico Bambino Gesù, Roma, Italy, [2]Dipartimento di Oncologia, Ematologia, Trapianto e Terapia Cellulare e Genica, Ospedale Pediatrico Bambino Gesù, Roma, Italy, [3]Università degli Studi La Sapienza, Roma, Italy

P54/ID 447

KIR Genotyping of Hematopoietic Stem Cell haploidentical donors: a single center experience

Francesco Ingrassia[1*], Alice Pecoraro[1*], Maria Blando[1], Alessia Angela Corica[1], Floriana Di Paola[1], Rosalba Bavetta[1], Serena Mistretta[1], Floriana Bruno[1], Giuseppe Davì[1], Angela Lo Brutto[1], Valentina Cappuzzo[1] and Roberta Fedele[1]

*[1]Laboratorio Regionale di Tipizzazione Tessutale ed Immunologia dei Trapianti – A.O.O.R. Villa Sofia-Cervello – Palermo, Italy. *contributed equally*

P55/ID 7887

Comparing accuracy of HLA typing from DNA extracted from blood and buccal samples for patients in remission from malignant hematological disease and healthy donors

Charlotte A. Cambridge[1], Gabriel J. Benitez[1], Jack Dishington[1], Neema P. Mayor[2] and Steven G.E. Marsh[2]

[1]Anthony Nolan Research Institute, London, UK, [2]Anthony Nolan Research Institute and UCL Cancer Institute, University College London, London, UK

P56/ID 7443

A novel HLA-DQA1*01 null allele identified in a Brazilian hematopoietic stem cell transplantation recipient affects the expression of HLA-DQ5 protein

Gisele F Rampim[1], Renata Fantini[1], Tuila B Mourão[1], Renato de Marco[1] and Maria Gerbase-DeLima[1]

[1]Immunogenetics Institute, Associação Fundo de Incentivo à Pesquisa, São Paulo, SP, Brazil

P57/ID 783

Haploidentical Stem Cell Transplantation in a patient sensitized with Donor Specific Antibodies

Serena Mistretta[1], Rosalba Bavetta[1], Floriana Bruno[1], Alessia Corica[1], Giuseppe Davì[1], Floriana Di Paola[1], Francesco Ingrassia[1], Alice Pecoraro[1], Maria Blando[1], Valentina Cappuzzo[1] and Roberta Fedele[1]

[1]Laboratorio Regionale di Tipizzazione Tessutale ed Immunologia dei Trapianti – A.O.O.R. Villa Sofia-Cervello – Palermo, Italy

P58/ID 1487

PCR-associated HLA-C allele drop-out in two related samples typed by next generation sequencing – a cautionary tale

Elizabeth De Mendonca[1], Thomas R. Turner[2,3], Ceylan Alushi[1], Jexray Sayno[1], Ravneet K. Bola[1], Reetinder Grewal[1], Michael Hoddinott[1], Raymond Fernando[4], Neema P. Mayor[2,3], Sandra Frater[1], Sharon Vivers[1,3], Franco Tavarozzi[1] and Lisa Walsh[1]

[1]Anthony Nolan Laboratories, London, UK, [2]Anthony Nolan Research Institute, London, UK, [3]UCL Cancer Institute, UCL Campus, London UK, [3]Solid Organ Group, Anthony Nolan, Royal Free Hospital, London, UK

P59/ID 1544

Two cases of HLA mistyping in patients with acute myeloid leukemia before transplantation

Sabine Wenda[1], Ingrid Faé[1], Cornelia Grill[2] and Gottfried Fischer[1]

[1]Medical+ University of Vienna, Vienna, Austria, [2]General Hospital of Vienna, Vienna, Austria

P60/ID 1236

Transplanting across a donor specific HLA antibody in hematopoietic stem cell transplantation

Zdenka Edwards[1], Sandra Frater[1], James Peat[1], Raymond Fernando[2], Lisa Walsh[1] and Sharon Vivers[3]

[1]Anthony Nolan, London, UK, [2]Royal Free Hospital, London, UK, [3]Anthony Nolan, UCL Cancer Institute, UCL Campus, London, UK

P61/ID 2703

Case report of a patient with acute myeloid leukemia complicated by recurrent hemophagocytic syndrome with pancytopenia and sepsis

Eva Miarkova[1] and Hana Cechova[2]

[1]Department of Immunohematology, [2]Department of Cell Chimerism, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

P62/ID 6682

Activities of the Macedonian Bone Marrow Donor Registry in the search and match process

Meri Kirijas[1], Boban Dobrevski[1], Gorjan Milanovski[1], Teodora Brnjarchevska Blazhevska[1], Tamara Savevska[1] and Aleksandar Petlichkovski[1]

[1]Institute of Immunobiology and Human Genetics, Faculty of Medicine, University Ss Cyril and Methodius in Skopje, Skopje, Republic of North Macedonia

P63/ID 2838

HLA-A, -B, -C, -DRB1, -DRB3/DRB4/DRB5, -DQA1, -DQB1, -DPA1, -DPB1 haplotypes in families of patients awaiting allogeneic hematopoietic stem cell transplantation

Ekaterina Khamaganova[1], Stanislav Khizhinskiy[1], Aliona Abdrakhimova[1], Evgeniy Leonov[1], Elena Kuzminova[1], Larisa Kuzmina[1] and Elena Parovichnikova[1]

[1]National Research Center for Hematology, Moscow, Russia

P64/ID 289

HLA-DRB3/4/5 and HLA-DRB1 allele and haplotype frequencies in hematological patients planned for hematopoietic stem cell transplantation

Barbara Jovanovic[1], Nikola Kacaki[1], Zorana Andric[1], Glorija Blagojevic[1] and Zeljka Nenadovic[1]

[1]Blood Transfusion Institute of Serbia, Belgrade, Serbia

P65/ID 4428

High-resolution HLA allele frequencies in unrelated populations determined by next generation sequencing

Andreea Caragea[1], Radu Ioan Ursu[1], Larisa Denisa Ursu[2], Ion Maruntelu[2], Adriana Talangescu[2], Mirela Maria Iacob2, Maria Tizu[2], Alexandra Gabriela Matei[3], Alexandra Cojocaru[3], Adelina Mariana Marin[3], Alexandra Bianca Mocanu[3], Simona Filimon[1], Anamaria Calin[3], Radu Alexandru Truica[3], Anisia Capitanu Reisler[3], Bianca Andreea Catana[3], Alex Stefan Calimente[3] and Ileana Constantinescu[3]

[1]Synevo, Bucharest, Romania, [2]Fundeni Clinical Institute, Bucharest, Romania, [3]Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

P66/ID 1739

The Automation of DNA Quantification and Normalization Workflow through the Introduction of the MaxPrep Liquid Handler

Fatima Moghnieh[1], Kyle Annette-Woodgate[1], Madalina Pinzaru[1] and Lisa Walsh[1]

[1]Anthony Nolan, London, UK

P67/ID 9790

External Proficiency Testing offered by the HLA Department of the Institute of Hematology and Blood Transfusion in Prague, Czech Republic: Detection of HLA Alleles Associated with Diseases

Nazarová S.[1], Zemánková L. [1], Půbalová Š. [1], Kinská B. [1], Vraná M[1]

[1]Institute of Hematology and Blood Transfusion, Prague, Czech Republic

Immunogenetics in Organ Transplantation

P68 /ID 1886

Adsorption with X-match cells and Elution (AXE) protocol testing to clarify HLA antibody reactivity in a highly sensitized patient

Sandra Tafulo[1] and Robert Liwski[2]

[1]Portuguese Institute for Blood and Transplantation, Lisbon, Portugal, [2]Dalhousie University, Halifax, Canada

P69/ID 3995

Imlifidase desensitization in a highly-sensitized kidney transplant recipient

Angeliki Vittoraki[1], Stathis Tsiakas[2], Eleni Stergiopoulou[1], Sofia Ioannou[1], Alexandra Siorenta[1], Athina Aikaterini Nikolaou[1], Sofia Nikolaou[1], Eirini Karchilaki[1], Vasiliki Vrani[1], Dimitra Skoumi[1], Smaragdi Marinaki[2], Maria Darema[2], Georgios Paterakis[1] and John N. Boletis[1]

[1]Immunology Department & National Tissue Typing Center General Hospital of Athens "G.Gennimatas", Greece, [2]Department of Nephrology and Renal Transplantation, Laiko Hospital, Athens, Greece

P70/ID 3527

Major histocompatibility class I chain-related gene A (MICA) mismatching and development of anti-MICA antibodies after heart transplantation

Marija Burek Kamenaric[1], Lucija Jukic[1], Marija Maskalan[1], Katarina Stingl Jankovic[1], Zorana Grubic[1], Bosko Skoric[1], Maja Cikes[1], Davor Milicic[1], Hrvoje Gasparovic[1] and Renata Zunec[2]

[1]Tissue Typing Centre, Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Zagreb, Croatia, [2]Department of Cardiovascular Diseases, University Hospital Centre Zagreb, Zagreb, Croatia

P71/ID 9737

Efficacy and limits of anti-Rituximab antibodies use in cross-matches for patients treated with Rituximab prior to kidney transplantation in Grenoble University Hospital

Johan Noble[1], Elodie Gautier-Veyret[2], Ornella Senoussi[3], Clara Manoukian[3], Dominique Masson[3], Béatrice Bardy[3], Thomas Jouve[1], Lionel Rostaing[4], Paolo Malvezzi[1] and Céline Dard[3]

[1]Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble Alpes University Hospital, France, [2]Laboratory of Pharmacology-Pharmacogenetics-Toxicology, Grenoble Alpes University Hospital, France, [3]Histocompatibility Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France

P72/ID 2383

Quantification of plasma and urine Annexin-V positive microparticles as biomarkers in a Donor Specific Antibody positive kidney transplant population

Valentine Jacob[1], Quentin De Berny[1], François Brazier[1], Claire Presne[1] and Nicolas Guillaume[1]

[1]Amiens University Medical Center, Amiens, France

P73/ID 136

Antibody monitoring in highly sensitized kidney transplant candidate with preformed donor specific antibodies and desensitized with Imlifidase before kidney transplantation. First case in Italy

Elisa Trovato Salinaro[1] and Maria Paola Albergoni[1]

[1]Transfusion Unit, Padua University Hospital, Padova, Italy

P74/ID 9213

Donor specific HLA-DPw antibodies in a highly sensitized kidney transplant recipient – a case report

Dolores Hrusovar[1], Natalija Pisec[1], Miha Arnol[2,3] and Blanka Vidan Jeras[1]

[1]Tissue Typing Center, Blood Transfusion Centre of Slovenia, Ljubljana, Slovenia, [2]Department of Nephrology, University Medical Centre Ljubljana, Ljubljana, Slovenia, [3]Medical Faculty, University of Ljubljana, Ljubljana, Slovenia

P75/ID 3365

High resolution HLA typing in kidney transplantation increases the access to transplant in highly sensitized patients

Francisco Javier Gil-Etayo[1,2], María Pilar Fraile-Gómez[3,4], Guadalupe Tabernero[2,3,4], Jairo Eduardo Niño Ramírez[1,2,4], Isabel Jiménez Hernaz[1], Pilar Terradillos Sánchez[1], Ana Balanzategui[1,2], Ariadna Vicente Parra[1], Ramón García Sanz[1,2,4,5,6] and Amalia Tejeda-Velarde[1,2]

[1]Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain, [2](IBSAL) Instituto de Investigación Biomédica de Salamanca. Salamanca, Spain, [3]Unidad de Trasplante Renal, Servicio de Nefrología, Hospital Universitario de Salamanca, Salamanca, Spain, [4]Universidad de Salamanca (USAL), Salamanca, Spain, [5]Centro de Investigación del Cáncer (CIC), Salamanca, Spain, [6]Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Spain

P76/ID 5429

HLA-Cw, -DQ and -DP relevance in cPRA calculation before and after kidney transplantation

Imen Daoud[1], Aida Charfi[1], Arwa Kamoun[1], Nadia Mahfoudh[1], Mondher Masmoudi[2], Soumaya Yaich[2], Lilia Gaddour[1], Faiza Hakim[1], Mohamed Ben Hmida[2] and Hafedh Makni[1]

[1]Histocompatibility and Immunology Laboratory, Hedi Chaker Hospital, Sfax, Tunisia, [2]Nephrology Department, Hedi Chaker Hospital, Sfax, Tunisia

P77/ID 2991

Selection of blood collection tube is crucial for accurate quantification of dd-cfDNA following solid organ transplant

Sofia Carlén[1] and Linnéa Pettersson[1]

[1]Devyser, Stockholm, Sweden

P78/ID 8714

The prozone effect – solving discrepancies in antibody testing in two cases

Tatjana Dukic[1], Jelena Dmitrovic[1] and Zorana Andric[1]

[1]Blood Transfusion Institute of Serbia, Belgrade, Serbia

P79/ID 2647

Impact of SARS-CoV-2 on HLA serological phenotyping level in southern Portugal solid organ donors

Ana Teixeira[1], Paula Almeida[1], Maria Isabel Silva[1], Dulce Roldão[1], Olga Abade[1], Pedro Mendonça[1], Cristiana Teixeira[1], Raquel Ferreira[1] and Luís Ramalhet[1]

[1]Centro Sangue e Transplantação de Lisboa- Area da Transplantação / Nova Medical School, Portugal

P80/ID 939

HLA-A, -B and -DRB1 Distributions Among End Stage Renal Disease Patients in the Turkish Population

Servet Uluer Biceroglu[1], Semiha Ozgul[2], Olcay Seckin Genek[1], Salime Seda Altan[1], Aygül Celtik[3], Ipek Kaplan Bulut[3] and Ayhan Donmez[1]

[1]Ege University Faculty of Medicine Tissue Typing Laboratory, İZMİR, Turkey,[2]Ege University Faculty of Medicine Department of Biostatistics and Medical Informatics, İZMİR, Turkey, [3]Ege University Faculty of Medicine Department of Nephrology, İZMİR, Turkey

P81/ID 6984

Sensitization of patients in need of kidney transplantation with HLA antibodies in the Republic of Kazakhstan

Aida Turganbekova[1], Zhulduz Zhanzakova[1], Zhazira Saduakas[1], Dana Baimukasheva[1], Didara Khamitova[2], Kuralay Zhangazieva[1] and Saniya Abdrakhmanova[1]

[1]Research and Production Center of Transfusion, Kazakhstan Ministry of Health, Astana, Kazakhstan

P82/1729

Transition from OneLambda to Immucor Single Antigen Bead assays for HLA Antibody Assessment Facilitates Access to Kidney Transplantation in Highly Sensitized Patients: a single-center experience

Corentin Streel[1], Arnaud Devresse[1], Yannick France[1], Valérie Dumont[1], Thibaut Gervais[1], Martine De Meyer[1], Tom Darius[1], Antoine Buemi[1], Michel Mourad[1], Eric Goffin[1], Véronique Deneys[1] and Nada Kanaan[1]

[1]Cliniques Universitaires Saint-Luc, UCLouvain, Bruxelles, Belgium

MHC Evolution, Population Genetics

P83/ID 195

Differences in Allele Frequencies in the MICA and MICB genes between Sardinian and Caucasian/European Population

Celeste Sanna[1], Stefano Mocci[1], Sara Lai[1], Roberto Littera[1], Roberta Stradoni[1], Alessia Mascia[1], Federica Cannas[1], Michela Lorrai[1], Caterina Mereu[1], Stefania Tranquilli[1], Stefania Rassu[1], Erika Giuressi[1], Rita Porcella[1], Francesco Alba[1], Nicola Orrù[1] and Sabrina Giglio[1]

[1]Medical Genetics Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy

P84/ID 343

Distribution of HLA-DRB3 alleles in Spanish population

Jairo Eduardo Niño Ramirez[1,2,3], Francisco Javier Gil-Etayo[1,2], Isabel Jiménez Hernaz[1,2], Pilar Terradillos Sánchez[1], Ariadna Vicente Parra[1], Ana Balanzategui[1,2,4,5], Miguel Bastos Boente[1,2,3], Miguel Alcoceba[1,2,4,5], Ramón García-Sanz[1,2,3,4,5] and Amalia Tejeda Velarde[1,2]

[1]Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain, [2]Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, [3]Universidad de Salamanca, Salamanca, Spain, [4]Centro de Investigación del Cáncer, Salamanca, Spain, [5]Centro de Investigación Biomédica en Red Cáncer, Spain

P85/ID 1053

Aggressive behavior in Italian children with ADHD in the middle of COVID-19 pandemic: preliminary data on MAOA gene polymorphisms involvement

Ludovico Neri[1], Valentina Nanni[1], Pierluigi Sebastiani[2], Alessia Colanardi[2], Tiziana Del Beato[2] and Anna Aureli[2]

[1]Child-adolescent Neuropsychiatry Unit, San Salvatore Hospital, L'Aquila, Italy, [2]CNR Translational Pharmacology, L'Aquila, Italy

P86/ID 1100

Haplotypes MICA-129Met/Val and HLA-B in the Russians population of Chelyabinsk region of Russian South Urals

Mikhail N. Vavilov[1], Tatiana A. Suslova[1] and Alexandra L. Burmistrova[1]

[1]Chelyabinsk State University, Chelyabinsk, Russia

P87/ID 1135

Study of HLA-B51 and HLA-B27 antigen expression in non-infectious uveitis

Aymen Tezeghdenti[1], Chaima Khadhraoui[1] and Najah Boussetta[1]

[1]Military Hospital of Tunis, Tunis, Tunisia

P88/ID 1139

Possibility of linkage disequilibrium between SNP-197 of IL17 and HLA class I and II in the Bashkir Chelyabinsk region

Daria Stashkevich[1] and Tatiana Suslova[2]

[1]Chelyabinsk State University, [2]Chelyabinsk State University, Chelyabinsk Blood Transfusion Station, Chelyabinsk, Russia

P89/ID 1168

Distribution of the MHC patterns of Mexican Mestizo populations from the states of Durango vs Oaxaca and Cdmx

Clara Gorodezky[1], Karen Rivera[1], Arlett Del Olmo[1], Alejandra Florentino[1], Ma. Dolores Ozuna[1], Miguel Carmona[1], Juan Antonio González[1] and Rafael Franco-Santillán[2]

[1]Laboratory of Immunology and Immunogenetics, Fundacion Comparte Vida A.C., CDMX, Mexico, [2]Instituto Nidiac Durango City, Durango, Mexico

P90/ID 2049

Recombination between HLA genes in two siblings

Ingrid Fae[1], Cornelia Grill[2], Sabine Wenda[1] and Gottfried Fischer[1]

[1]Medical University of Vienna, Vienna, Austria, [2]General Hospital Vienna, Vienna, Austria

P91/ID 2354

Insertion/ deletion polymorphism of angiotensin-converting enzyme and susceptibility of psoriatic arthritis in a south Tunisian population

Mariem Maaloul[1], Aida Charfi[1], Arwa Kamoun[1], Afef Feki[2], Nadia Mahfoudh[1], Faiza Hakim[1], Lilia Gaddour[1], Sofiene Baklouti[2] and Hafedh Makni[1]

[1]Immunology and Histocompatibility Department, University Hospital Hedi Chaker Hospital, Sfax, Tunisia, [2]Rheumatology Department, University Hospital Hedi Chaker Hospital, Sfax, Tunisia

P92/ID 2401

Association between migraine and HLA-B and HLA-DRB1 gene polymorphisms in a southern Croatia population

Sonja Jaman[1,2], Matea Tarabene[1], Barbara Stanić[1], Lucija Meštrović[3] and Esma Čečuk-Jeličić[1,2]

[1]Tissue Typing Laboratory, Division of Blood Transfusion University Hospital of Split, Split, Croatia, [2]University Department of Health Studies, University of Split, Split, Croatia [3]Faculty of Medicine, Josip Juraj Strossmeyer University, Osijek, Croatia

P93/ID 2782

Next-generation sequencing reveals and validates HLA polymorphism among Croatians

Marija Maskalan[1], Zorana Grubic[1], Katarina Stingl Jankovic[1], Marija Burek Kamenaric[1], Lucija Jukic[1] and Renata Zunec[1]

[1]Tissue Typing Centre, University Hospital Centre Zagreb, Zagreb, Croatia

P94/ID 2875

DRB1*04:02 allele: the DR4 associated with DRB4*01:03:01:02N in the Spanish population

Jairo Eduardo Niño Ramirez[1,2,3], Francisco Javier Gil-Etayo[1,2], Isabel Jiménez Hernaz[1], Pilar Terradillos Sánchez[1], Ariadna Vicente Parra[1], Ana Balanzategui[1,2,4,5], Miguel Bastos Boente[1,2,3], Miguel Alcoceba[1,2,4,5], Ramón García-Sanz[1,2,3,4,5] and Amalia Tejeda-Velarde[1,2]

[1]Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain, [2]Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain, [3]Universidad de Salamanca, Salamanca, Spain, [4]Centro de Investigación del Cáncer, Salamanca, Spain, [5]Centro de Investigación Biomédica en Red Cáncer, Spain

P95/ID 3318

Serological equivalents of rare HLA alleles in French population

Dominique Masson[1], Mathilde Cherel[2], Isabelle Jollet[3], Barbara Proust[3], Jean-Luc Taupin[4] and Alexandre Walencik[5]

[1]Histocompatibility Laboratory, Etablissement Français du Sang Rhone Alpes – Grenoble, France, [2]Histocompatibility Laboratory, Etablissement Français du Sang Bretagne, Rennes, France, [3]Histocompatibility Laboratory, Etablissement Français du Sang Aquitaine, Poitiers, France, [4]Histocompatibility Laboratory, Hôpital Saint-Louis, Paris, France, [5]Histocompatibility Laboratory, Etablissement Français du Sang Centre-Pays de la Loire, Nantes

P96/ID 3576

Distribution of Mhc-C encoded C1 and C2 epitopes and inhibitory KIR repertoire potential in West-African chimpanzees and humans

Natasja de Groot[1], Corrine Heijmans[1], Jesse Bruijnesteijn[1], Alicia Sanchez-Mazas[2] and Ronald E. Bontrop[1,3]

[1]Biomedical Primate Research Centre, [2]University of Geneva, [1]Comparative Genetics and Refinement, Biomedical Primate Research Centre, Rijswijk, Netherlands, [2]Department of Genetics and Evolution – Anthropology Unit, University of Geneva and Institute of Genetics and Genomics of Geneva (IGE3), Geneva, Switzerland, [3]Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands

P97/ID 3678

Identification of 8-Digit HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1 and -DRB1 allele and haplotype frequencies in a South Tunisian population

Aida Charfi[1], Mariem Maaloul[1], Arwa Kamoun[1], Stéphane Buhler[2], Delphine Mouron[2], Jean Villard[2], Alicia Sanchez-Mazas[3], Jose Manuel Nunes[4], Faiza Hakim[1], Lilia Gaddour[1], Hafedh Makni[1] and Nadia Mahfoudh[1].

[1]Immunology and Histocompatibility Laboratory, University Hospital Hedi Chaker, Sfax, Tunisia, [2]University Hospital, Geneva, Switzerland, [3]Department of Genetics and Evolution, Anthropology Unit, University of Geneva, Geneva, Switzerland, [4]Institute of Genetics and Genomics, Geneva, Switzerland

P98/ID 3918

Endoplasmic reticulum aminopeptidase gene polymorphism and susceptibility of psoriatic arthritis in a south Tunisian population

Mariem Maaloul[1], Aida Charfi[1], Nadia Mahfoudh[1], Afef Feki[2], Arwa Kamoun[1], Lilia Gaddour[1], Faiza Hakim[1], Sofiene Baklouti[2] and Hafedh Makni[2]

[1] Immunology and Histocompatibility Laboratory, University Hospital Hedi Chaker, Sfax, Tunisia, [2]Rheumatology Department, University Hospital Hedi Chaker, Sfax, Tunisia

P99/ID 3997

Distribution of the HLA-DPA1 and -DPB1 alleles in a South Tunisian population

Aida Charfi[1], Mariem Maaloul[1], Arwa Kamoun[1], Stéphane Buhler[2], Delphine Mouron[2], Jean Villard[2], Alicia Sanchez-Mazas[3], Jose Manuel Nunes[4], Faiza Hakim[1], Lilia Gaddour[1], Hafedh Makni[1] and Nadia Mahfoudh[1]

[1]Immunology and Histocompatibility Laboratory, University Hospital Hedi Chaker, Sfax, Tunisia, [2]University Hospital, Geneva, Switzerland, [3]Department of Genetics and Evolution, Anthropology Unit, University of Geneva, Geneva, Switzerland, [4]Institute of Genetics and Genomics, Geneva, Switzerland

P100/ID 4169

Detection of HLA-A and HLA-J haplotype diversity from next-generation sequencing data in commercially available samples

Jessica Edwards[1], Danial Shamsuddin[1], Christopher Newbound[1] and Curtis Lind[1]

[1]CareDx Pty Ltd, Australia

P101/ID 4547

Association between HLA and SARS-COV-2 infection in Mexican Mestizos

Karen Rivera[1], Ma. Dolores Ozuna[1], Ricardo Peral[1], Araceli Rodríguez[1,2] and Clara Gorodezky[1].

[1]Laboratory of Immunology and Immunogenetics, Fundacion Comparte Vida, A.C, CDMX, Mexico, [2]Institute of Epidemiological Diagnosis and Reference, InDRE, CDMX, Mexico.

P102/ID 5029

HLA-C Allele-Sharing Associated with High Viral load (HIV-1 RNA) Increases the Risk of HIV-1 Transmission among Heterosexual Serodiscordant Couples in Nigeria

Ngozi Otuonye[1], Ma Luo[2], Maureen Aniedobe[1] and Nkiruka Odunukwe[1]

[1]Nigerian Institute of Medical Research, Central Research Laboratory, Yaba, Lagos, Nigeria, [2]National Medical Laboratory, Canada

P103/ID 5660

Unravelling the architecture of Major Histocompatibility Complex class II regions in a primate species

Nanine de Groot[1], Jesse Bruijnesteijn[1], Marit van der Wiel[1], Natasja de Groot[1] and Ronald E. Bontrop[1,2]

[1]Comparative Genetics and Refinement, Biomedical Primate Research Centre, Rijswijk, Netherlands, [2]Theoretical Biology and Bioinformatics, Utrecht University, Utrecht, Netherlands

P104/ID 6166

Identification of a rare association between DRB1*01:01 and DRB5 using and an NGS method

Maria Troiano[1], Tiziana Galluccio[1], Annalisa Guagnano[1], Giuseppe Testa[1], Andrea Di Luzio[1] and Marco Andreani[1]

[1]Laboratorio di Immunogenetica dei Trapianti, Ospedale Pediatrico Bambino Gesù, Rome, Italy

P105/ID 6539

The genetic impact of changes in mating patterns driven by post-war relocation of population and economic development

Chryso Pieridou[1,2], Andri Papaloizou[2], Georgios Kallis[2], Marios Georgiou[2], Anita Koumouli[2] and Paul Costeas[1,2]

[1]The Karaiskakio Foundation, Nicosia, Cyprus, [2]The Center for the Study of Hematological Malignancies, Nicosia, Cyprus

P106/ID 6771

New HLA alleles identified in the admixed Brazilian population

Tânia K. de Araujo[1,2], Douglas C. Rosa[1,2], Fábio R. Torres[1,2], Fernando Cendes[2,3] and Iscia Lopes-Cendes[1,2]

[1]Department of Translational Medicine, School of Medical Sciences, University of Campinas (UNICAMP) Campinas, SP, Brazil, [2]Brazilian Institute of Neuroscience and Neurotechnology (BRAINN), Campinas, SP Brazil, [3]Department of Neurology, School of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, Brazil

P107/ID 7158

Comparison of two single antigen bead assays for detection of anti-HLA antibodies and evaluation of their reactivity with complement binding

Georgios Lioulios[1], Konstantinos Ouranos[1], Manolis Panteli[1], Marianthi Papachristou[2], Aliki Xochelli[2], Artemis Maria Iosifidou[1], Chatzika Georgia[2], George Petasis[2], Maria Stangou[1] and Asimina Fylaktou[2]

[1]Department of Nephrology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece, [2]Department of Immunology, National Peripheral Histocompatibility Center, Hippokration Hospital, Thessaloniki, Greece

P108/ID 8479

Impact of TNF-alpha gene polymorphisms on the risk and clinical manifestations of Ulcerative Colitis

Olivia Mihaela Popa[1], Cristian Tieranu[1], Monica Dutescu[2], Mihai Bojinca1 and Luis Popa[3]

[1]University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, [2]'Prof. Dr. C. T. Nicolau' National Institute of Blood Transfusion, Bucharest, Romania, [3]"Grigore Antipa" National Museum of Natural History, Bucharest, Romania

P109/ID 9027

Comparative analysis of HLA-haplotype distributions in two Slavic populations

Elena Kuzmich[1], Irina Pavlova[1], Alena Hlaz[2], Tatyana Glazanova[1], Anastasia Pavlova[1], Anatoly Ihar Iskrou[2], Siarhei Liashchuk[2] and Ludmila Bubnova[1]

[1]Russian Research Institute of Hematology and Transfusiology, Saint-Petersburg, Russia, [2]Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology, Minsk, Belarus

NK cells & KIR

P110/ID 9581

Selective HLA haplotype loss and immunological escape of NPM1+ AML

Giovanni Rombolà[1], Beatrice Boschi[1], Irene Donnini[2], Giuseppina Marseglia[1], Clara Ballerini[3], Sara Iozzi[1], Michela Falco[4], Franco Papola[5], Roberto Crocchiolo[6], Sabrina Frusconi[1] and Elisabetta Pelo[1]

[1]SOD Diagnostica Genetica, AOU Careggi, Florence, Italy, [2]Medicina Trasfusionale, AOU Careggi, Florence, Italy, [3]Neuroimmunologia Università di Firenze, Florence, Italy, [4]Laboratorio Immunologia IRCCS Gaslini, Genova, Italy, [5]Centro Regionale Immunoematologia e Tipizzazione Tissutale, L'Aquila, Italy, [6]Immunoematologia e Medicina Trasfusionale GOM Niguarda, Milan, Italy

P111/ID 1490

HLA-E and its NKG2 receptors in graft-versus-host disease

Jagoda Siemaszko[1], Anna Czyż[2], Agnieszka Szeremet[2], Maciej Majcherek[2], Małgorzata Sobczyk-Kruszelnicka[3], Wojciech Fidyk[3], Sebastian Giebel[3], Barbara Nasiłowska-Adamska[4], Iwona Solarska[4], Agnieszka Tomaszewska[5], Grzegorz W. Basak[5], Maria Bieniaszewska[6], Patrycja Skowrońska[6], Tomasz Wróbel[3] and Katarzyna Bogunia-Kubik[1]

[1]Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland, [2]Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Wrocław, Poland, [3]Department of Bone Marrow Transplantation and Hematology-Oncology, Institute of Oncology, Gliwice, Poland, [4]Institute of Hematology and Blood Transfusion, Warsaw, Poland, [5]Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, [6]Department of Hematology and Transplantology, Medical University of Gdansk, Gdańsk, Poland

P112/ID 2762

The extent of non-expressed KIR3DL1 alleles in a French population

Nolwenn Legrand[1], Enora Ferron[1], Perla Salameh[1], Gaelle David[1], Marie-Claire Devilder[1], Catherine Willem[1,2], Ketevan Gendzekhadze[3], Peter Parham[4], Christelle Retiere[1,2,4] and Katia Gagne[1,2,4,5]

[1] Nantes Université, EFS, INSERM, CNRS, CRCI2NA, Nantes, [2]LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France, [3]HLA Laboratory, Department of Hematology and HSCT, City of Hope, Medical Center, CA, USA; [4]Departments of Structural Biology and Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA, [5]LabEx Transplantex, Université de Strasbourg, Strasbourg, France

P113/ID 1575

Allele frequencies for three framework Killer cell Immunoglobulin Like Receptor genes in the Western Australian population

Jonathan Downing[1], Fredrick Mobegi[1], Lloyd D'Orsogna[1], Patricia Martinez[1] and Dianne De Santis[1]

[1]Clinical Immunology, PathWest, Fiona Stanley Hospital, Perth, Australia

P114/ID 5332

Allele-level characterization of KIR gene polymorphism in healthy elderly from four populations – Bulgarian, Romanian, Polish and Turkish

Bushra Hadra[1], Tsvetelin Lukanov[1], Ileana Constantinescu[2], Fatma Oguz[3], Dimitri Apostol[2], Yeliz Ogret[3], Katarzyna Bogunia-Kubik[4], Katarzyna Koscinska[5], Marta Dratwa[4], Adriana Talangescu[2], Alexandra-Elena Constantinescu[2], Ion Maruntelu[2], Anastasiya Mihaylova[6] and Elissaveta Naumova[1]

[1]University Hospital Alexandrovska, Medical University, Sofia, Bulgaria, [2]Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, [3]Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, [4]Hirszfled Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland, [5]HLA Laboratory, Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland, [6]Department of Clinical Immunology and Stem Cell Bank, University Hospital Alexandrovska, Sofia, Bulgaria

P115/ID 7447

Short and Long Read sequencing data analysis of co-located Killer-cell Immunoglobulin-like Receptor genes 2DS3 and 2DS5

Bram Luiken[1], Loes van de Pasch[1], Linda Ouwerkerk[1], Anne Manders[1], Erik Rozemuller[1] and Maarten Penning[1]

[1]GenDx, Utrecht, Netherlands

P116/ID 4691

KIR3DS1/HLA-Bw4 in Tunisian patients with chronic myeloid leukemia

Sirine Louati[1], Aida Charfi[1], Arwa Kammoun[2], Frikha Rim[3], Nadia Mahfoudh[1], Faiza Hakim[1], Lilia Gaddour[1], Hassen Kamoun[3] and Hafedh Makni[1]

[1]Histocompatibility and Immunology Laboratory, Hedi Chaker Hospital, Sfax, Tunisia, [2]Histocompatibility and Immunology Laboratory, Renal Pathology Laboratory, Hedi Chaker Hospital, Sfax, Tunisia, [3]Genetic Department, Hedi Chaker Hospital, Sfax, Tunisia

P117/ID 5940

KIR3DS1/HLA-Bw4 distribution in the Tunisian population

Sirine Louati[1], Aida Charfi[1], Arwa Kamoun[1], Nadia Mahfoudh[1] and Hafedh Makni[1]

[1]Histocompatibility and Immunology Laboratory, Hedi Chaker Hospital, Sfax, Tunisia

New technologies & New Approaches in Immunogenetics

P118/ID 3860

A Modern twist on Compatibility Assessment in the Histocompatibility and Immunogenetics Laboratory

Alison Logan[1], Kay Poulton[1] and Douglas Dyer[2]

[1]Transplantation Laboratory Manchester Royal Infirmary, Manchester, UK, [2]University of Manchester, Manchester, UK

P119/ID 2048

The NanoTYPE Experience: Nanopore Sequencing as a New Tool for HLA Laboratories Enabling Routine and Urgent High-Resolution Typing

Gregory Werner[1], Nina Lauterbach[2], Libor Kolesar[3] and Krisztina Rigó[4]

[1]Omixon Biocomputing Ltd, Switzerland, [2]Omixon Biocomputing Ltd, Netherlands, [3]Omixon Biocomputing Ltd, Czech Republic, [4]Omixon Biocomputing Ltd, Hungary

P120/ID 500

Long read phased sequencing of HLA class I and II genes using MinION Sequencing

Dianne De Santis[1], Naser El-Lagta[1], Linh Truong[1], Felipe Ayora[2], Fredrick Mobegi[1] and Lloyd D'Orsogna[1]

[1]Department of Clinical Immunology, PathWest, Fiona Stanley Hospital, Murdoch, WA, Australia, [2]BizData, New Zealand

P121/ID 9993

Results of the 6 Month Post-Transplant Surveillance in patients transplanted with preformed donor-specific anti-HLA antibodies (DSA) by Adding Donor-Derived Cell-Free DNA (ddcfDNA) Testing

Maria Lasa-Lazaro[1], Miriam Velasco-Sidro[1], Tamara Ruiz Merlo[2], Natalia Polanco[3], Isabel Perez Flores[4], María José Castro-Panete[1], Estela Paz-Artal1 and Esther Mancebo[1]

[1]Department of Immunology, University Hospital "12 de Octubre", Instituto de Investigación Sanitaria (imas12), Madrid, Spain, [2]Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Madrid, Spain, [3]Instituto de Investigación Sanitaria imas12, [4]Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain

P122/ID 8430

Evaluating recent nanopore sequencing chemistries for rapid and conventional HLA typing

Pascal van der Weele[1], Marcel van de Streek[1], Sjoerd Creutzburg[1], Bart Valkenburg[1], Ioannis Nemparis[1], Joris Albers[1], Loes van de Pasch[1] and Maarten Penning[1]

[1]GenDx, Utrecht, Netherlands

P123/ID 9319

Evaluation of the Nanotype™ assay for high-resolution hla typing

Gisele F Rampim[1], João H Campos[1], Tuila B Mourão[1], Valentina Proença[1], Eder F Sousa[1], Renato de Marco[1] and Maria Gerbase-DeLima[1]

[1]Immunogenetics Institute, Associação Fundo de Incentivo à Pesquisa, São Paulo, SP, Brazil

P124/ID 6620

Evaluation of the Magelia for automated purification of Caredx® Alloseq HCT kit libraries in the context of post-hematopoietic stem cells transplantation chimerism assessment

Coralie Frassati[1], Pascal Pedini[1], Sandrine Fabre[2], Agnes Basire[2], Sophie Simon[2], Sebastian Aguilar Pierlé[3], Joseph Santucci[3], Camille Soucies[3], Amel Bendali[3], Arthur Sterin[4], Gerard Michel[4] and Christophe Picard[1]

[1]Etablissement Français du Sang, Marseille, France 2. ADES UMR 7268, Aix Marseille Univ, Marseille, France, [2]Immunogenetics Laboratory, Etablissement Français du Sang PACA Corse, France, [3]Inorevia, Paris, France, [4]Department of Pediatric Hematology-Oncology, Hôpital Enfants la Timone, Marseille, France

P125/ID 4098

Evaluation of the HISTO TYPE Rainbow kit from BAG DIAGNOSTICS at the HLA EFS laboratory in Marseille

Coralie Frassati[1], Jean-Baptiste Baudey[1], Lucas Buson[1], Lucas Hubert[1], Sophie Simon[1], Agnès Basire[1], Pascal Pedini[2] and Christophe Picard[1]

[1]Immunogenetics Laboratory, Etablissement Français du Sang 2. ADES UMR 7268, Aix Marseille Univ, Marseille, France, [2]Etablissement Français du Sang PACA Corse, France

P126/ID 5592

Open Science in human immunogenetics; challenges and pathways

Anne Cambon-Thomsen[1]

[1]CNRS and Université Toulouse III Paul Sabatier, Toulouse, France

P127/ID 9012

Identification of the novel HLA-DPB1*02:01:68 allele in a Greek individual

Diamanto Kouniaki[1], Katerina Tarassi[1], Vassiliki Kitsiou[1], Theofilos Athanassiades[1], Konstantinos Fotopoulos[1] and Alexandra Tsirogianni[1]

[1]Immunology-Histocompatibility Dept., Evangelismos Hospital, Athens, Greece

P128/ID 6244

Identification and characterization of six novel HLA alleles by next generation sequencing in Spanish population during the last year

Amalia Tejeda Velarde[1], Francisco Javier Gil-Etayo[1], Jairo Eduardo Niño Ramírez[1], Antonio Balas[2], Alberto Torío[3], Ariadna Vicente Parra[1], Isabel Jiménez Hernaz[1], Pilar Terradillos Sánchez[1], Ana Balanzategui[1], Miguel Alcoceba[1] and Ramón García Sanz[1]

[1]Laboratorio de HLA-Biología Molecular, Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain [2]Histocompatibilidad, Centro de Transfusión de la Comunidad de Madrid, Madrid, Spain, [3]Sección de Inmunología, Hospital Regional Universitario de Málaga, IBIMA, Spain

P129/ID 5782

Identification of the novel HLA-A*01:426 allele in a Greek individual

Diamanto Kouniaki[1], Vasiliki Kitsiou[1], Theofilos Athanassiades[1], Katerina Tarassi[1], Konstantinos Fotopoulos[1] and Alexandra Tsirogianni[1]

[1]Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece

P130/ID 1622

Identification of the novel HLA-A*02:09:01:04 allele in a Greek individual

Diamanto Kouniaki[1], Theofilos Athanassiades[1], Katerina Tarassi[1], Vassiliki Kitsiou[1], Konstantinos Fotopoulos[1] and Alexandra Tsirogianni[1]

[1]Immunology and Histocompatibility Department, Evangelismos General Hospital, Athens, Greece

SATELLITE SYMPOSIA

THURSDAY, April 27, 2023

Room 300 *(Lower Foyer)*

12:10–13:10 **CareDx**
Breaking New Ground: Innovative Pre-and Post-Transplant Solutions to Improve Allograft Outcomes

Moderator: *Curtis Lind – VP, Head of R&D Products*

CareDx®
Your Partner in Transplant Care™

High Resolution HLA Typing with AlloSeq Tx – the Experience of National HLA Laboratory, Bucharest
Monica Irina Dutescu, MD, PhD

Comparison of Next-Generation Sequencing and Short-Tandem Repeats to Monitor Chimerism Analysis
Miguel Alcoceba, PhD

dd-cfDNA in Allograft Rejection and Risk Assessment
Olivier Aubert, MD, PhD

Room 300 *(Lower Foyer)*

13:20–14:20 **Immucor**
Exploring New Frontiers in Transplantation Testing

IMMUCOR

The role of HLA and non-HLA antibody burden in the outcome of pediatric kidney transplantation
Dr. Patrizia Comoli – Fondazione IRCCS Policlinico San Matteo di Pavia – Italy

A modelling approach for Mean Fluorescence Intensity value harmonization and cut-off prediction for Luminex Single Antigen Bead assays of two different vendors
Dr. Gonca Karahan – LUMC – Netherlands

FRIDAY, April 28, 2023

Room 300 *(Lower Foyer)*

12:10–13:10 **GenDx**
Exploring new worlds for HLA and Chimerism: Dare to discover innovative solutions

GENDX

Tsvetelin Lukanov – Assistant Professor at the Department of Clinical Immunology, Medical University Sofia

Lukas Frischknecht MD PhD – Co-director Transplant Immunology, University Hospital Zurich

Maaike Rijkers – PhD Project Manager R&D at GenDx

Room 300 *(Lower Foyer)*

13:20–14:20 **One Lambda Inc. a Thermo Fisher Scientific Brand**
Enhancing the Transplant Experience: The Journey Continues

Moderator: *Jean-Luc Taupin, PhD – Saint-Louis Hospital, Paris, France*

ONE LAMBDA
A Thermo Fisher Scientific Brand

Evolution of HLA Typing by NGS – from Homemade Reagents to the AllType™ FASTplex™ Kit
Ioannis Theodorou, MD, PhD – Laboratory of Immunology, Hospital Robert Debre | Paris, France

To be or not to be a Donor Specific Antibody – the Importance of Widening the View with SAB Expanded Panels
Sandra Tafulo, PhD – HLA Alosensitization Laboratory, Instituto Portugues de Sangue e da Transplantacao, Porto, Portugal

Room 150 *(Lower Foyer)*

14:30–15:30 **Omixon**
New Horizons in HLA Typing

omixon

A new dawn in identifying protective immunity for Neglected Tropical Diseases
Wim Adriaensen – Clinical Immunology, Institute of Tropical Medicine

New Era of HLA Typing: Advantages and Chances of the NanoTYPE
Dr. rer. nat. Claudia Lehmann – Transplantation Immunology, University Hospital Leipzig

Epitope matching in renal transplantation, an Odyssey
Prof., Dr. rer. nat., Dipl. Biol. Ilias Doxiadis – Transplantation Immunology, University Hospital Leipzig

CareDx

Visit us at Booth #1

Patrick G., Kidney transplant recipient

Breaking New Ground: Innovative Pre- and Post-Transplant Solutions to Improve Allograft Outcomes

Thursday 27 April, 2023 | 12.10 - 13.10

Room: 300

Symposium sponsored by CareDx

REGISTER

SYMPOSIUM ENDORSED BY EFI

Save the date and join us to explore the latest perspectives of leaders in the pre- and post-transplant space.

Moderator

Curtis Lind - VP, Head of R&D Products
CareDx

Speakers

High Resolution HLA Typing with AlloSeq Tx – the Experience of National HLA Laboratory, Bucharest
Monica Irina Dutescu, MD, PhD
National HLA Laboratory, National Institute of Blood Transfusion Prof. Dr. C.T. NICOLAU
Bucharest, Romania

Comparison of Next-Generation Sequencing and Short-Tandem Repeats to Monitor Chimerism Analysis
Miguel Alcoceba, PhD
Department of Haematology, University Hospital of Salamanca (HUS-IBSAL)
Salamanca, Spain

dd-cfDNA in Allograft Rejection and Risk Assessment
Olivier Aubert, MD, PhD
Necker-Enfants Malades Hospital - Paris Transplant Group
Paris, France

Event: Meet us in Person

Join us for
Immucor's Sponsored Symposium

EXPLORING NEW FRONTIERS IN TRANSPLANTATION TESTING

Thursday 27th April 2023: 13:20 - 14:20

Room 300, Lower Foyer

La Cité des Congrès de Nantes, Nantes, France

A modelling approach for Mean Fluorescence Intensity value harmonization and cut-off prediction for Luminex Single Antigen Bead assays of two different vendors

Gonca Emel Karahan, PhD

Leiden University Medical Center, Department of Immunology, Laboratory for Transplantation Immunology, Leiden, the Netherlands

The role of HLA and non-HLA antibody burden in the outcome of pediatric kidney transplantation

Patrizia Comoli, MD

Fondazione IRCCS Policlinico San Matteo, GMP Facility and Center for Advanced Cellular Therapies, Pavia, Italy

Session Chaired by: Dr Christine Heylen, Senior Director, International Commercial Scientific Affairs, Immucor

JOIN & DISCOVER

GENDX SYMPOSIUM

Exploring new worlds for HLA and Chimerism: Dare to discover innovative solutions

NGS-defined KIR polymorphism: novel insights and future prospects

Tsvetelin Lukanov PhD

New technologies for rapid HLA typing: first experiences with NGS-Turbo®

Lukas Frischknecht MD PhD

A retrospective comparison study of chimerism monitoring by NGS and qPCR

Maaike Rijkers PhD

ROOM 300

FRIDAY APRIL 28, 12:10 - 13:10

experts in transplant diagnostics

GENDX

Yalelaan 48 | 3584 CM Utrecht | Utrecht Science Park
The Netherlands | +31 (0)30 252 3799 | www.GenDx.com

ThermoFisher SCIENTIFIC

EFI 2023

ONE LAMBDA SYMPOSIUM

Enhancing the Transplant Experience: The Journey Continues

Friday, April 28 | 13:20-14:20 | Room 300

Next Generation Sequencing (NGS) workflows have revolutionized transplant immunology by enabling more comprehensive HLA genotyping. Extended Single Antigen coverage, which includes additional HLA antibody specificities, allows for better matching between donors and recipients and may lead to improved graft survival and reduced risk of rejection. Join us to learn more from our guest speakers who will share their experiences with these technologies, their decision-making process for virtual crossmatching, as well as using epitope matching to help provide better outcomes for transplant patients.

MODERATOR

Jean-Luc Taupin, PhD | Saint-Louis Hospital | Paris, France

SPEAKERS

Evolution of HLA Typing by NGS - from Homemade Reagents to the AllType™ FASTplex™ Kit

Ioannis Theodorou, MD, PhD
Laboratory of Immunology
Hospital Robert Debre | Paris, France

To Be or Not to Be a Donor Specific Antibody – the Importance of Widening the View with SAB Expanded Panels

Sandra Tafulo, PhD
HLA Alosensitization Laboratory
Instituto Portugues de Sangue e da Transplantacao | Porto, Portugal

ONE LAMBDA
A Thermo Fisher Scientific Brand

EFI 2023

JOIN OMIXON'S SYMPOSIUM AT EFI 2023

NEW HORIZONS IN HLA TYPING

WHEN? Fri 28 April 14:30-15:30

WHERE? Cité des congrès de Nantes
Lower Foyer, Room 150

Wim Adriaensen, PhD
Clinical Immunology
Institute of Tropical Medicine

A NEW DAWN IN IDENTIFYING PROTECTIVE IMMUNITY FOR NEGLECTED TROPICAL DISEASES

Vaccine development for many neglected tropical diseases (NTDs) is confronted with scientific challenges in target antigen identification and the lack of correlates of protection. Causes are unsuitable preclinical models, genomic complexity of the pathogens, and the remoteness of the affected and poverished populations. Recent technological evolutions facilitate a new dawn in antigen discovery and defining protective immunity for complex diseases in remote settings. I will present the implementation of our novel pipeline in Ethiopia and how the NanoTYPE part of this platform facilitated our mission.

Dr. rer. nat. Claudia Lehmann
Transplantation Immunology
University Hospital Leipzig

NEW ERA OF HLA TYPING:
ADVANTAGES AND CHANCES OF THE NANOTYPE

High-resolution HLA-typing is done in a transplant immunology diagnostic laboratory. Time is always a limiting factor. Especially when urgent samples, as postmortem organ donors must be typed. Oxford-Nanopore-Sequencing brings new opportunities for high-resolution HLA-typing. Here, we present first experiences with Omixon NanoTYPE in our laboratory. The first validation results will be shown, the protocol including the NanoTYPE software is examined/evaluated from a diagnostic laboratory perspective. The advantages are the long reads, which means that e.g. DPB1 can be resolved without cis/trans ambiguities. New technologies are associated with challenges in the handling of large amounts of data and must be planned.

Prof., Dr. rer. nat., Dipl. Biol. Ilias Doxiadis
Transplantation Immunology
University Hospital Leipzig

EPITOPE MATCHING IN RENAL TRANSPLANTATION, AN ODYSSEY

The goal in renal transplantation is to achieve long term patient and graft survival. Cell mediated rejections are thought to be treatable, while humoral rejections are on the long term deleterious. The antigens of the HLA system are in essence the main targets for the antibodies. Accurate HLA typings of organ recipients and donors and definition of the antibody specificity are the state of the art. Incompatible epitopes recognized by specific antibodies are defined. Avoiding them, graft survival rate will increase. Consequently, by predicting epitopes which might lead to antibody production will allow a better organ allocation.

PARTNERS

PLATINUM PARTNERS

CareDx®
Your Partner in Transplant Care™

CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers.

CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. With over 20 years of leadership in 4 areas of transplant innovation, our understanding of transplant patients and care teams allows us to develop solutions to extend graft life. With two decades of commitment to transplant care, we have developed close partnerships across the transplant ecosystem that grow stronger every day. CareDx is a global, 100% transplant focused company, demonstrating leadership in serving laboratories, researchers, and clinicians with its state-of-the-art product portfolio of next-generation sequencing (NGS) based AlloSeq products, which serve as pre- and post-transplantation solutions. For pre-transplant application, CareDx offers HLA typing solutions QTYPE and AlloSeq Tx. For post-transplantation monitoring, CareDx offers AlloSeq HCT chimerism testing and AlloSeq cfDNA for labs to measure the relative amount of donor derived cfDNA (dd-cfDNA) in solid organ transplant recipients. All products are CE marked. For research purposes, CareDx also provides AlloSeq Tx and AlloSeq cfDNA testing as services for customers who prefer to use the CareDx service lab in Stockholm, Sweden. Learn more about CareDx transplant lab products: https://caredx.com/products-and-services/transplant-lab-products/.

GENDX

GenDx

For more than 15 years, GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitor success of transplantation. We combine our renowned software and reagents for high resolution HLA typing by Next Generation Sequencing and Chimerism monitoring with excellent customer support and education. We work closely with our partners and clients and share knowledge to advance the field of transplant typing and monitoring. With a highly educated and motivated team of almost 100 people and 40 distributors we contribute worldwide to the quality of life of transplant patients. **Board of Directors –** Per October 4, 2022, the Paris, France-based Eurobio Scientific acquired all outstanding shares of GenDx. The board of director currently consists of Wietse Mulder PhD (executive director), Denis Fortier and Hervé Duchesne de Lamotte (non-executive directors). **Our Mission & Vision –** Improve the quality of life and survival of transplant patients & advance the field of transplantation by offering excellent molecular diagnostic tools and sharing knowledge.

Immucor

Seeing Beyond Limits

New Frontiers in Transplant Diagnostics

Founded in 1982, Immucor® is a global leader of transfusion and transplantation diagnostics. Our transplant diagnostics portfolio provides molecular and antibody-based assays for compatibility between donors and recipients. Laboratories use our products as part of determining the best path forward for a solid organ and bone marrow transplant recipient and monitoring for possible post-transplant rejection. Our LIFECODES® products and MIA FORA™ deliver highly accurate testing solutions for donor-patient compatibility. We are also leading the way in post-transplant monitoring with our innovative antibody and molecular assays that detect early signs of rejection. Finally, our specialty diagnostic solutions for platelet transfusion testing and hemostasis provide important diagnostic information for today's modern laboratories. By providing clinicians with accurate test results, we can help change the practice of transplant medicine.

ONE LAMBDA

A Thermo Fisher Scientific Brand

One Lambda

As part of Thermo Fisher Scientific, we offer products and services to advance the science of transplant diagnostics. Our solutions help transplant labs and clinical teams provide personalized care across the patient experience Dr. Paul Terasaki founded One Lambda™ in 1984 with the goal of developing tests to improve how laboratories match and monitor transplant recipients and donors. Since then, our HLA typing and antibody detection assays have been trusted by transplant laboratories worldwide. Clinicians also rely on data from our patient monitoring tests to make important decisions about post-transplant therapies. Transplantation is life-changing for recipients, and clinical diagnostics play a vital role in supporting all phases of treatment. Through our commitment to scientific innovation, product quality, patient advocacy, and excellent customer service, we are helping the transplant community raise the standard of care and improve outcomes for patients and their families.

GOLD PARTNER

OMIXON BIOCOMPUTING LTD.

Omixon is a global transplantation diagnostic company with a mission to provide histocompatibility laboratories with innovative technologies to improve transplant outcomes. Omixon is headquartered in Budapest, Hungary, with operations in the United States, Brazil and the Netherlands serving more than 60 laboratories worldwide. Building on multidisciplinary competences in bioinformatics, software engineering, molecular biology and regulatory science, Omixon transforms molecular biology innovations into stateof-the-art products in transplant diagnostics. Omixon was the first to successfully introduce a next generation sequencing (NGS) based HLA genotyping kit and software in 2014 by bringing Holotype HLA product and HLA Twin software to market. HLA Twin delivers the most accurate high-resolution HLA genotyping and is used in more than 60+ laboratories worldwide. Omixon was the first to release a high resolution HLA genotyping product NanoTYPE HLA with less than 5 hours turnaround time on the Oxford Nanopore sequencing platform complemented by NanoTYPER analysis software. Omixon is the first to bring to market a donor-derived cell-free DNA kit HoloGRAFT for laboratories with donor-informative genetic markers with primer and probe sequences that are absent in the patient genotype by design.

SILVER PARTNER

Devyser

Towards a new level of certainty

Devyser – Your post-transplant companion

We are pioneers in diagnostic kits and solutions for advanced DNA testing. Our goal is to eliminate tedious protocols and streamline laboratory workflows with simple, fast, and easyto-use solutions. So all patients receive a correct diagnosis and faster treatment in the shortest time possible. **Our mission –** Be the pioneering leader of diagnostic solutions and provide fast, accurate, and easy-to-use solutions to labs worldwide. **Our vision –** A world where personalized medicine is universally available thanks to simplified and reliable genetic tests.

BRONZE PARTNERS

DKMS Life Science Lab

HISTOGENETICS

BAG DIAGNOSTICS

HANSA BIOPHARMA

STEMCELL™ TECHNOLOGIES

SOCIAL PROGRAM

WELCOME COCKTAIL

Date: Wednesday, April 26, 2023, 19:30–21:00
Place: Great Auditorium + Great Gallery foyers – Congress venue
The Welcome Cocktail is open to all conference participants.

NETWORKING EVENT 1 / CONFERENCE GALA DINNER

Date: Friday, April 28, 2023, 20:00–23:00
20:00–21:00 Visit of the mechanical sculpture gallery
21:00–23:00 Conference Dinner
Place: Les Machines de l'île
(address: Parc des Chantiers, Boulevard Léon Bureau, 44 200 Nantes)
Recommended dress code: Smart casual
Price: 95 € / per person

NETWORKING EVENT 2 / AFTER PARTY

Date: Friday, April 28, 2023, 23:00–02:00
Place: Stereolux Club
(address: Parc des Chantiers, 4 Boulevard Léon Bureau, 44 200 Nantes)
Recommended dress code: Smart casual
Price: 35 € / per person
Snacks and drinks are paid by each participant

GENDX TULIP RUN

Date: Friday, April 28, 7:00 am
Price: 25 € / per person
The tickets will be available for sale until April 27, 2023, 18:00.
Meeting point: At the main entrance of La Cité des Congrès de Nantes
Program: 06:40 am Warm-up
07:00 am Start Run
08:00 am Tulip run awards & heading back to the hotel

Custom Lab Service

State-of-art typing services
Accurate, detailed, clearly presented results
Send your samples from anywhere in the world



Services

- High resolution HLA typing
  Also available for KIR, MICA, MICB, non-classical HLA genes
- Chimerism testing
  Using qPCR or NGS
- HLA-loss detection
- New allele service
- Haplotype/frequency analysis
- Multipattern analysis
- GoToMeetings with experts

experts in transplant diagnostics

GENDX

Yalelaan 48 | 3584 CM Utrecht | Utrecht Science Park
The Netherlands | +31 (0)30 252 3799 | www.GenDx.com

NGS Essentials

ThermoFisher SCIENTIFIC

Does Your DNA Purification Method for NGS Really Matter?

Learn about purification methods with Maureen, an NGS Technical Training Specialist

Maureen Montgomery
Sr. Technical Training Specialist
Thermo Fisher Scientific

> “it’s imperative to consider all the downstream applications when incorporating a new extraction method”

Tell us a bit about your job and journey in the field of HLA?
I am the Sr. Technical Training Specialist for our One Lambda branded NGS products. Before joining Thermo Fisher’s Transplant Diagnostics business, I spent 20 years working in the HLA Clinical Laboratories at the University of North Carolina and LabCorp using a variety of One Lambda products. I worked mainly on the molecular side with the validation of NGS assays and some R&D work as well. ***Read more online...***

Why is DNA Purification so important?
The quality of your DNA is critical to the results of your assay. If you have genomic DNA that is not intact (has small fragment sizes), it will greatly limit the quality of results and how successful they are. Ensuring a quality starting material is key to obtaining the best results possible. ***Read more online...***

Are all DNA extraction methods the same?
No - all DNA extraction methods are not the same. There are several ways to extract DNA, such as magnetic beads, spin columns and filter plates, among several others. It is crucial to the success of molecular assays that the DNA does not contain PCR inhibitors. ***Read more online...***

Visit our website to read the rest of Maureen’s thoughts on DNA Purification for NGS.

Read more online

Visit us at EFI at booth #4

ONE LAMBDA
A Thermo Fisher Scientific Brand



Devyser Accept cfDNA

A new method for dd-cfDNA detection **Booth #6**

Dvysr®

www.devyser.com

HISTOGENETICS

HIGH QUALITY FAST HLA TYPING USING THE BEST SEQUENCING TECHNOLOGIES

JOIN US ON APRIL 27, 6PM - 8PM
POSTER VIEWING
WINE & CHEESE RECEPTION

SCAN TO SEE OUR SERVICES

WWW.HISTOGENETICS.COM

SAVE THE DATE

See You in Jerusalem

37th European Immunogenetics & Histocompatibility Conference

May 20–23, 2024
International Convention Center
Jerusalem, Israel

Why Jerusalem?

Is one of the most fascinating cities in the world: It presents a unique combination of ancient history, spiritual sanctity and colorful cultures providing an extraordinary location for an exciting and memorable experience.

Is still one of the world's most multicultural societies: on its streets one might meet Jews from all four corners of globe, speaking in a plethora of tongues; Palestinian Arabs (both Muslim and Christian); and priests, monks, and nuns of all Christian denominations.

Dotting the landscape are sacred sites – from the splendid Dome of the Rock/Temple Mount, to Gethsemane, as well as monuments and museums dedicated to history and memory, such as the Yad Vashem Center, and the Shrine of the Book. The medley of languages, customs and costumes, smells and tastes, is intoxicating.

It is bursting with shopping, nightlife, dining and culture to rival any major city. The colorful Mahane Yehuda market, charming Nahalat Shiva and bustling Ben Yehuda pedestrian mall and Jaffa Road. Each has its own unique personality and charm that you won't want to miss out on.

Iconic Mix of Modernity and History – Only in Jerusalem will you network with your peers in a city with history going back over 3,000 years ago.

www.efi-conference.org

EFI 2024 Conference, Jerusalem, Israel
37th European Immunogenetics & Histocompatibility Conference

EFI 2023

36TH EUROPEAN IMMUNOGENETICS AND HISTOCOMPATIBILITY CONFERENCE

April 26–29, 2023, Nantes, France

Big Data in Immunogenetics at the Crossroads of Care, Tools and Research